WO2006010546A2 - Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors - Google Patents

Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors Download PDF

Info

Publication number
WO2006010546A2
WO2006010546A2 PCT/EP2005/007894 EP2005007894W WO2006010546A2 WO 2006010546 A2 WO2006010546 A2 WO 2006010546A2 EP 2005007894 W EP2005007894 W EP 2005007894W WO 2006010546 A2 WO2006010546 A2 WO 2006010546A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
phenyl
pyridin
benzenesulfonamide
chloro
Prior art date
Application number
PCT/EP2005/007894
Other languages
French (fr)
Other versions
WO2006010546A3 (en
Inventor
Kurt Amrein
Daniel Hunziker
Bernd Kuhn
Alexander Mayweg
Werner Neidhart
Original Assignee
F. Hoffman-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0513864-7A priority Critical patent/BRPI0513864A/en
Priority to NZ552398A priority patent/NZ552398A/en
Application filed by F. Hoffman-La Roche Ag filed Critical F. Hoffman-La Roche Ag
Priority to DK05776709T priority patent/DK1789041T3/en
Priority to JP2007522984A priority patent/JP4690402B2/en
Priority to PL05776709T priority patent/PL1789041T3/en
Priority to DE602005008079T priority patent/DE602005008079D1/en
Priority to CA2574875A priority patent/CA2574875C/en
Priority to AU2005266531A priority patent/AU2005266531B2/en
Priority to MX2007000789A priority patent/MX2007000789A/en
Priority to EP05776709A priority patent/EP1789041B1/en
Publication of WO2006010546A2 publication Critical patent/WO2006010546A2/en
Publication of WO2006010546A3 publication Critical patent/WO2006010546A3/en
Priority to IL180481A priority patent/IL180481A/en
Priority to NO20070458A priority patent/NO20070458L/en
Priority to HK07114003.9A priority patent/HK1105592A1/en
Priority to HR20080477T priority patent/HRP20080477T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention is concerned with novel pyrimidine derivatives useful as llb- HSDl inhibitors (T2D).
  • the invention is concerned particularly with compounds of formula I
  • R 1 is hydrogen, alkyl, cycloalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, amino or aminoalkyl;
  • R 2 is hydrogen, alkyl or halogen
  • R 3 is hydrogen, alkyl or halogen
  • R 4 is phenyl, naphtyl, thiophenyl, pyridyl, quinolyl, piperidyl, morpholyl or thiomorpholyl optionally substituted with one or more substituents independently selected from alkyl, cycloalkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, cyano, trifluoromethyl, trifluoromethoxy, aryl, arylalkyl, aryloxy, heterocyclyl, alkylcarbonylamino, alkoxycarbonylalkoxy and alkyl-SO 2 - ;
  • R 5 is hydrogen or alkyl;
  • A is nitrogen or C-R 10 ;
  • E is nitrogen or C-R 9 ;
  • G is nitrogen or C-R 8 ;
  • Glucocorticoids (Cortisol in humans, corticosterone in mice and rats) are an important class of adrenocorticosteroids that regulate many metabolic and homeostatic processes and form a key component of the response to stress. Glucocorticoids act via intracellular glucocorticoid receptors and, in some tissues, mineralocorticoid receptors; both being nuclear transcription factors. Glucocorticoid action on target tissues depends not only on circulating steroid concentrations and the cellular expression of receptors, but also on intracellular enzymes that critically determine to which extent glucocorticoids gain access to receptors in an active forms.
  • 1 lbeta-hydroxysteroid dehydrogenases catalyze the interconversion of the principal active 11 -hydroxy-glucocorticoid (Cortisol in men) and their inactive 11-keto metabolites (cortisone in men).
  • the enzyme 1 lbeta-hydroxysteroid dehydrogenase type 1 (llbeta-HSDl) inter- converts inactive into active glucocorticoids, thereby playing a major role in local modulation of cellular agonist concentration and thus activation of corticosteroid receptors in target tissues.
  • llbeta-HSDl The enzyme 1 lbeta-hydroxysteroid dehydrogenase type 1 (llbeta-HSDl) inter- converts inactive into active glucocorticoids, thereby playing a major role in local modulation of cellular agonist concentration and thus activation of corticosteroid receptors in target tissues.
  • Ih a recent study made by F. Hoffmann-La Roche differences in gene expression in lean and obese men were analyzed using gene array technology in order to identify specific changes in gene expression that might be associated with insulin resistance or altered metabolism. This study revealed that the mRNA for 1 lbeta-HSDl is approximately two-fold up regulated in adipos
  • the first pharmacological indication tnat llbeta-HSDi innibmon in men might have beneficial effects were obtained by using carbenoxolone, an anti-ulcer drug which inhibits both 1 lbeta-HSDl and the related enzyme 1 lbeta-HSD2.
  • carbenoxolone an anti-ulcer drug which inhibits both 1 lbeta-HSDl and the related enzyme 1 lbeta-HSD2.
  • Treatment with carbenoxolone led to an increase in insulin sensitivity indicating that that inhibition of 1 lbeta-HSDl may reduce cellular Cortisol levels and therefore minimizing some of its deleterious effects. (Walker et al. 1995; J. Clin. Endocrinol. Metab. 80, 31155-3159).
  • 1 lbeta-HSDl is expressed in many tissues including liver, adipose tissue, vascular smooth muscles, pancreas and brain. Its activity is dependent on NADP(H) and it has a relatively low affinity for its substrate (compared to llbeta-HSD2). 11 beta-HSDl in tissue homogenates and when purified is bidirectional, exhibiting both 1 lbeta-dehydrogenase and llbeta-reductase reactions, with greater stability of the dehydrogenase activity (P.M. Stewart and Z.S. Krozowski, Vitam. Horm. 57 (1999), pp. 249-324).
  • the 1 lbeta-reductase activity predominates, which regenerates active glucocorticoids from inert 11-keto forms.
  • Such glucocorticoid regeneration will increase effective intracellular glucocorticoid levels and thereby amplifying glucocorticoid activity. It is this elevated cellular Cortisol concentration that might lead to increased hepatic glucose production, adipocyte differentiation and insulin resistance.
  • Inhibition of 1 lbeta-HSDl should not only reduce the typical Syndrome-X / Diabetes associated symptoms, but it should also be save and without major side effect.
  • Studies with the unspecific inhibitor carbenoxolone highlight the importance of developing specific 1 lbeta-HSDl inhibitors.
  • the inhibition of the llbeta-HSD2 enzyme is badly tolerated and results in increased blood pressure.
  • inhibition of 1 lbeta- HSDl should be well tolerated since 1 lbeta-HSDl knockout mice were found be healthy and to resist hyperglycemia provoked by obesity or stress (Kotelevtsev Y. et al., Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14924-9).
  • mice Similar upon starvation these mice had attenuated activation of key hepatic enzymes that are involved in gluconeogenesis. In addition, these mice had improved lipid and lipoprotein profiles suggesting that inhibition of HSDl might be highly efficacious and safe.
  • 1 lbeta-HSDl inhibitors might also be beneficial to reduce high blood pressure (Masuzaki H. et al., J Clin Invest. 2003 July;112(l):83-90; Rauz S. et al., QJM. 2003 July;96(7):481-90) to improve cognition (Sandeep TC. et al., Proc Natl Acad Sci U S A. 2004 Apr. 27;101(17):6734-9) or to improve Alzheimer associated deficits. Taken together llbeta-HSDl inhibition might be a save and efficacious approach to treat symptoms of diabetes, obesity and other diseases.
  • the compounds of formula I and their pharmaceutically acceptable salts and esters are novel and have valuable pharmacological properties.
  • they are 1 Ib-HSDl inhibitors (T2D) and they display selectivity against the related llbeta-HSD2 enzyme. Therefore the compounds which are specific llbeta-HSDl inhibitors (T2D) represent an approach to e.g. lower blood glucose levels and normalize lipid parameters in Type 2 diabetic patients by modulating the local concentration of the active glucocorticoid Cortisol in target tissue (liver, adipose tissue).
  • the compounds of the present invention can be used in the prophylaxis and/or treatment of metabolic disorders, obesity, dyslipidemiae, hypertension and/or diabetes, particularly diabetes Type II.
  • the compounds of this invention can further be used in the prophylaxis and/or treatment of high ocular eye pressure, cognition, Alzheimer and/or neurodegeneration.
  • Objects of the present invention are the compounds of formula I and their aforementioned salts and esters per se and their use as therapeutically active substances, a process for the manufacture of the said compounds, intermediates, pharmaceutical compositions, medicaments containing the said compounds, their pharmaceutically acceptable salts and esters, the use of the said compounds, esters and salts for the prophylaxis and/or therapy of illnesses, especially in the treatment or prophylaxis of eating disorders, obesity, dyslipidemiae, hypertension and/or diabetes, particularly diabetes Type II, and the use of the said compounds, salts and esters for the production of medicaments for the treatment or prophylaxis of metabolic disorders, obesity, dyslipidemiae, hypertension and/or diabetes, particularly diabetes Type II.
  • the compounds of the present invention can further be combined with PPAR (alpha, gamma, delta) agonists, DHEA (dehydroepiandrosterone), DPPIV inhibitors, insulin and/or lipase inhibitors, particularly orlistat.
  • PPAR alpha, gamma, delta
  • DHEA dehydroepiandrosterone
  • DPPIV inhibitors insulin and/or lipase inhibitors, particularly orlistat.
  • alkyl signifies a straight-chain or branched-chain alkyl group with 1 to 8 carbon atoms, preferably a straight or branched-chain alkyl group with 1 to 6 carbon atoms and particularly preferred a straight or branched-chain alkyl group with 1 to 4 carbon atoms
  • straight- chain and branched C 1 -C 8 alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.
  • cycloalkyl signifies a cycloalkyl ring with 3 to 8 carbon atoms and preferably a cycloalkyl ring with 3 to 6 carbon atoms.
  • Examples of C 3 -C 8 cycloalkyl are cyclopropyl, methyl-cyclopropyl, dimethylcydopropyl, cyclobutyl, methyl- cyclobutyl, cydopentyl, methyl-cyclopentyl, cyclohexyl, methyl- cydohexyl, dimethyl- cyclohexyl, cycloheptyl and cyclooctyl, preferably cyclopropyl.
  • alkoxy alone or in combination, signifies a group of the formula alkyl-
  • alkyl has the previously given significance, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec. butoxy and tert.butoxy, preferably methoxy and ethoxy and most preferred methoxy.
  • hydroxyalkyl signifies an alkyl group as defined before, wherein one or more hydrogen atoms, preferably one hydrogen atom is replaced by a hydroxy group.
  • hydroxyalkyl are hydroxymethyl and hydroxyethyl.
  • aryl signifies a phenyl or naphthyl group, preferably a phenyl group which optionally carries one or more substituents, preferably one to three, each independently selected from halogen, trifluorornethyl, trifluoromethoxy, amino, alkyl, alkoxy, alkylcarbonyl, cyano, carbamoyl, alkoxycarbamoyl, methylendioxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkyaminocarbonyl, dialkylaminocarbonyl, hydroxy, nitro, alkyl-SO 2 -, amino-SO 2 -, cycloalkyl and the like.
  • phenyl or naphthyl particularly phenyl optionally substituted with one to three, preferably one or two substituents independently selected from alkyl, halogen, alkoxy, trifluoromethoxy, nitro and trifluoromethyl. Particularly preferred is phenyl.
  • aryloxy alone or in combination, signifies a aryl-O- group in which the term “aryl” has the previously given significance.
  • heterocyclyl alone or in combination signifies a saturated, partially unsaturated or aromatic 5- to 10-membered heterocycle which contains one or more hetero atoms selected from nitrogen, oxygen and sulphur. If desired, it can be substituted on one or more carbon atoms e.g. by halogen, alkyl, alkoxy, oxo etc. and/or on a secondary nitrogen atom (i.e.
  • alkyl, cycloalkyl, aralkoxycarbonyl, alkanoyl, phenyl or phenylalkyl or on a tertiary nitrogen atom (i.e. N-) by oxido, with halogen, alkyl, cycloalkyl and alkoxy being preferred.
  • heterocyclyl groups are pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyrazoyl, imidazoyl (e.g.
  • Preferred examples are thiophenyl, quinolyl, piperidyl, morpholyl, thiomorpholyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazolyl, imidazolyl and thiazolyl.
  • amino signifies a primary, secondary or tertiary amino group bonded via the nitrogen atom, with the secondary amino group carrying an alkyl or cycloalkyl substituent and the tertiary amino group carrying two similar or different alkyl or cycloalkyl substituents or the two nitrogen substitutents together forming a ring, such as, for example, -NH 2 , methylamino, ethylamino, dimethylamino, diethylamino, methyl-ethylamino, pyrrolidin-1-yl or piperidino etc., preferably primary amino, dimethylamino and diethylamino and particularly dimethylamino.
  • halogen alone or in combination, signifies fluorine, chlorine, bromine or iodine and preferably fluorine, chlorine or bromine.
  • carbonyl alone or in combination, signifies the -C(O)- group.
  • nitro alone or in combination signifies the -NO 2 group.
  • salts refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable.
  • the salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, preferably hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxylic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcystein and the like.
  • salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like.
  • Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polymine resins and the like.
  • the compound of formula I can also be present in the form of zwitterions. Particularly preferred pharmaceutically acceptable salts of compounds of formula I are the hydrochloride salts.
  • the compounds of formula I can also be solvated, e.g. hydrated.
  • the solvation can be effected in the course of the manufacturing process or can take place e.g. as a consequence of hygroscopic properties of an initially anhydrous compound of formula I (hydration).
  • pharmaceutically acceptable salts also includes physiologically acceptable solvates.
  • “Pharmaceutically acceptable esters” means that compounds of general formula (I) maybe derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compounds in vivo. Examples of such compounds include physiologically acceptable and metabolically labile ester derivatives, such as methoxymethyl esters, methylthiomethyl esters and pivaloyloxymethyl esters. Additionally, any physiologically acceptable equivalents of the compounds of general formula (I), similar to the metabolically labile esters, which are capable of producing the parent compounds of general formula (I) in vivo, are within the scope of this invention.
  • the compounds of formula I can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereioisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates.
  • Another preferred object of the present invention are the compounds of formula I, wherein R 2 is hydrogen. Further preferred are those compounds according to formula I, wherein R 2 is alkyl. Particularly preferred are those compounds of formula I, wherein R 2 is methyl.
  • Another preferred aspect of the present invention are compounds of formula I, wherein R 5 is hydrogen.
  • Another preferred aspect of the present invention are the compounds of formula I, wherein G is C-R 8 . Also preferred are those compounds of formula I, wherein G is nitrogen.
  • R 4 is phenyl, naphtyl, thiophenyl, pyridyl, quinolyl, piperidyl, morpholyl or thiomorpholyl optionally substituted with one to three, preferably one or two substituents independently selected from alkyl, cycloalkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, cyano, trifluoromethyl, trifluoromethoxy, aryl, arylalkyl, aryloxy, heterocyclyl, alkylcarbonylamino, alkoxycarbonylalkoxy and alkyl-SO 2 - .
  • R is phenyl optionally substituted with one to three substituents independently selected from alkyl, cycloalkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, cyano, trifluoromethyl, trifluoromethoxy, aryl, arylalkyl, aryloxy, heterocyclyl, alkylcarbonylamino, alkoxycarbonylalkoxy and alkyl-SO 2 -.
  • R 4 is phenyl substituted with one to three substituents independently selected from alkyl, halogen and trifluoromethyl.
  • R 6 , R 7 , R 8 , R 9 and R 10 are independently selected from hydrogen, alkyl, halogen and trifluoromethyl.
  • Compounds of general formula I can be obtained according to scheme 1 from compounds of formula II comprising R 1 to R 7 substituents and A, E, G definitions according to the above description via a condensation reaction with aryl, heteroaryl or heterocydyl sulfonyl chlorides, in the presence of a base such as trietylamine or (4- dimetylamino) -pyridine (DMAP) in a solvent such THF, ethanol, methylene chloride DMF or DMSO, or in pyridine as a solvent, with or without the addition of a base such as trietylamine or DMAP, at room temperature or at elevated temperatures, to give compounds of general formula I.
  • Compounds of formula I where R 5 equals alkyl can also be prepared from compounds of formula I where R5 equals H via an alkylation reaction, using, for example, NaH as a base and DMF as solvent, at room temperature or at elevated temperatures.
  • compound of general formula I can be prepared according to scheme 2 from compounds of general formula III in a substitution reaction with an corresponding aryl heteroaryl or heterocyclyl sulphonamide, in the presence of a base such as sodium hydride, Na 2 CO 3 or triethyl amine and in a solvent such as THF, DMF or DMSO at room temperature or at elevated temperatures.
  • the reaction can also be carried out under the condition of an Ullman-type reaction with, for example Cu(I) chloride, or Cu(I) iodide in a solvent such as dioxane or DMF, in analogy to a method described by S. L. Buchwald (J. Am. Chem. Soc, 2001, 7727).
  • a further alternative consists of reacting compounds of general formula IV via a metal- catalysed (Pd or Ni) cross-coupling reaction with corresponding organometallic reagent such as (hetero)arylboron, (hetero)arylzink or (hetero)aryltin reagents using Suzuki-, Stille- or Negishi-type coupling reactions (for literature: Suzuki, Chem. Rev., 1995, 95, 2475; Stifle, Angew. Chem. IEE, 1986, 25, 508; Negishi, Ace. Chem. Res., 1982, 15, 340).
  • organometallic reagent such as (hetero)arylboron, (hetero)arylzink or (hetero)aryltin reagents using Suzuki-, Stille- or Negishi-type coupling reactions
  • reaction with alkyl amines or ammonia either applied in access, without solvent, or in equimolar amounts, in a suited solvent such as ethanol, water, DMF or THF, gives rise to compounds of formula VII.
  • a suited solvent such as ethanol, water, DMF or THF.
  • the reaction can also be performed in an autoclave at elevated pressure in analogy to published procedures (for an example: T. Haga, Heterocyles, 22, pi 17).
  • Compounds of formula II can then be be prepared from VII via a metal- catalysed (Pd or Ni) cross-coupling reaction with corresponding organometallic reagent such as (hetero)arylboron, (hetero)arylzink or (hetero)aryltin reagents using Suzuki-, Stille- or Negishi-type coupling reactions as descibed above.
  • organometallic reagent such as (hetero)arylboron, (hetero)arylzink or (hetero)aryltin reagents using Suzuki-, Stille- or Negishi-type coupling reactions as descibed above.
  • the amino group can optionally be protected with standard protecting groups such as BOC or pivaloyl prior to performing the cross-coupling reaction.
  • Compounds of formula III are obtained from compounds of formula VIII (prepared from V via metal-catalysed cross-coupling as for II) by an halogenation reaction (as for the preparation of VI).
  • Compounds of formula IV can be prepared from VI via a nudeophilic substitution reaction with a corresponding aryl, heteroayryl or heterocycylyl sulfonamide in a solvent such as DMSO or DMF in the presence of a base such as sodium hydride, at room temperature or at elevated temperature.
  • a base such as sodium hydride
  • the sulfonamides used in this step are either commercial, known in the literature or can be obtained by standard procedures known in the art. They can also first be converted into their sodium or potassium and these salts can then be used in the reaction, a procedure which does not require the addition of further base.
  • IV can be obtained from VII by reacting with the corresponding aryl, heteroaryl or heterocyclyl sulfonyl chlorides as described above.
  • a preferred process for the preparation of a compound of formula I, wherein R 1 to R 7 , A, E and G are defined as before comprises the reaction of a compound according to formula
  • R 1 to R 7 , A, E and G are defined as before.
  • a base such as trietylamine or (4- dimetylamino) -pyridine (DMAP)
  • a solvent such THF, ethanol, methylene chloride DMF or DMSO, or in pyridine as a solvent, with or without the addition of a base such as trietylamine or DMAP, at room temperature or at elevated temperatures.
  • an object of the present invention are compounds as decribed above for the preparation of medicaments for the prophylaxis and therapy of illnesses which are caused by disorders associated with the enzyme 1 lbeta-hydroxysteroid dehydrogenasel (HbHSDl).
  • compositions comprising a compound of the formula I as described above and a therapeutically inert carrier.
  • a further preferred embodiment of the present invention is the use of a compound of the formula I as described above for the preparation of medicaments for the treatment and prophylaxis of diabetes, obesity, eating disorders, dyslipidemiae and hypertension.
  • a further object of the present invention comprises a compound according to formula I as described above, when manufactured according to any one of the described processes.
  • an object of the invention is a method for the treatment and prophylaxis of diabetes, obesity, eating disorders, dyslipidemiae and hypertension, which method comprises administering an effective amount of a compound of formula I as described above.
  • Particularly preferred is a method for the treatment and prophylaxis of diabetes Type II, which method comprises administering an effective amount of a compound according to formula I as described above.
  • the resulting pellet was resuspended in storage buffer (2OmM Tris pH 7.5; 1 mM EDTA; 10% Glycerol) and the centrifugation was repeated. The resulting pellet containing the microsomal fraction was again taken up into storage buffer and aliquots were kept frozen in liquid Nitrogen until use.
  • Microsomes isolated from HEK293 cells transiently expressing human llbeta-HSDl were incubated in assay buffer (100 mM NaCl; ImM EDTA; ImM EGTA; ImM MgCl; 250 mM Sucrose; 20 mM Tris pH 7.4; Cortisone 50-20OnM and NADPH ImM) together with different concentrations of test substances. After 60 min. of incubation at 37 0 C the assay was stopped by heating to 80 0 C (5 min.) and by addition of the inhibitor Carbenoxolone (1 uM).
  • the amount of Cortisol produced in this assay was determined using a commercially available, ELISA-based Cortisol-detection kit (Distributed by Assay Design, Inc.). Inhibitors were characterized by there IC50 values, e.g. the concentration at which the production of Cortisol was 50% reduced.
  • preferred compounds as described above have IC50 values below 1000 nM; more preferred compounds have IC50 values below 100 nM. Most preferred compounds have IC50 values below 1OnM.
  • HEK293 cells stably expressing human llbeta-HSDl were cultivated in 96 well plates in DMEM. First inhibitors and 60 min later Cortisone was added to the cells. After 60 min of incubation at 37°C in a 5% CO2 atmosphere part of the medium was removed and the conversion from Cortisone to Cortisol was measured using a commercially available ELISA kit (Distributed by Assay Design, Inc.).
  • the compounds of formula I and their pharmaceutically acceptable salts and esters can be used as medicaments (e.g. in the form of pharmaceutical preparations).
  • the pharmaceutical preparations can be administered internally, such as orally (e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatin capsules, solutions, emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in the form of suppositories).
  • the administration can also be effected parentally, such as intramuscularly or intravenously (e.g. in the form of injection solutions).
  • the compounds of formula I and their pharmaceutically acceptable salts and esters can be processed with pharmaceutically inert, inorganic or organic adjuvants for the production of tablets, coated tablets, dragees and hard gelatin capsules.
  • Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragees and hard gelatin capsules.
  • Suitable adjuvants for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid substances and liquid polyols, etc.
  • Suitable adjuvants for the production of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose, etc.
  • Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc.
  • Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semi-solid or liquid polyols, etc.
  • the pharmaceutical preparations can contain preservatives, solubilizers, viscosity-increasing substances, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • the compounds of formula I and their pharmaceutically acceptable salts can be used for the prophylaxis and treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity.
  • the dosage can vary in wide limits and will, of course, be fitted to the individual requirements in each particular case.
  • Example 4b a) In analogy to example 1, on reaction of 5-(2-cMoro-phenyl)-6-methyl-pyridin-2- ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro- N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid.
  • Example 9 In analogy to example 1, on reaction of 5- (2,4-difluoro-phenyl) -pyridin-2-ylamine with 5- fluoro-2-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Difluoro- phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide as a crystalline white solid.
  • Example 12 In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-pyridin-2-ylamine with 5- fluoro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4-fluoro- phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a crystalline off-white solid.
  • Example 16 In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 2,4- dichloro-6-methyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5-(2- chloro-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide as a colourless crystalline solid.
  • Example 31 In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4- fluoro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a light-yellow solid.
  • Example 35 In analogy to example 1, on reaction of 5-(2,4-dicHoro-phenyl)-pyridin-2-ylamine with 3- chloro-4-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5 ⁇ (2,4- dicMoro-phenyl) -pyridin-2-yl] -4-methyl-benzenesulfonamide as an crystalline white solid.
  • Example 41 In analogy to example 1, on reaction of 5-(2,5-dichloro-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,5- dichloro- ⁇ henyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid.
  • Example 48 In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 4- trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro- phenyl) -pyridin-2-yl] -4-trifluoromethyl-benzenesulfonamide as a crystalline white solid.
  • Example 57 In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 4-acetylamino3-chloro-benzenesulfonyl chloride there was obtained: N- ⁇ 2-Chloro-4- [5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylsulfamoyl] -phenyl ⁇ -acetamide as a light- brown solid.
  • Example 71 In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 4- chloro-2,5-dimethyl-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5-(2,4- dichloro- ⁇ henyl)-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide as an amorphous white solid. ISN mass spectrum, m/e: 439 (M-I calculated for C 19 H 15 Cl 3 N 2 O 2 S: 439).
  • Example 79 In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-py ⁇ idin-2-ylamine with 4- trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro- phenyl)-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide as a white solid.
  • Example 83 In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 3- trifluromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)- pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 411 (M-I calculated for Ci 8 Hi 2 ClF 3 N 2 O 3 S: 411).
  • Example 87 In analogy to example 1, on reaction of 5-(2,4-dichloro- ⁇ henyl)-pyridin-2-ylamine with 4- ethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro-phenyl)-pyridin- 2-yl]-4-ethyl-benzenesulfonamide as a crystalline white solid.
  • Example 93 In analogy to example 1, on reaction of 5-(2-cHoro-phenyl)-pyridin-2-ylamine with 4- chloro-2,5-dimethyl-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5-(2- chloro-phenyl)-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide as a white solid.
  • Example 100 In analogy to example 1, on reaction of 5-(2,4-chloro-phenyl)-6-methyl-pyridin-2- ylamine with 4-chloro-2,5-dimethyl-benzenesulfonyl chloride there was obtained: 4- Chloro-N-[5-(2,4-dichloro-phenyl)-6-methyl-pyridin-2-yl]-2,5-dimethyl- benzenesulfonamide as a white powder.
  • Example 103 a In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 4-chloro-benzenesulfonyl chloride there was obtained: 4-Chloro-N- [5-(2,4-dichloro- phenyl)-pyridin-2-yl]-benzenesulfonamide as an off-white foam.
  • Example 104 In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-6- methyl-pyridin-2-yl]-3-fluoro-benzenesulfonamide as an light-yellow foam.
  • Example 107 In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 2,4-dichloro-5-methyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N- [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-5-methyl-benzenesulfonamide as a light- yellow foam.
  • ISN mass spectrum, m/e: 439 (M-I calculated for Ci 9 H 15 Cl 3 N 2 O 2 S: 439).
  • Example 110 In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin- 2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4- fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 389 (M-I calculated for Ci 9 H 16 ClFN 2 O 2 S: 389).
  • Example 111 Example 111
  • Example 113 In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin- 2-ylamine with 3-methyl-benzenesulfonyl chloride there was obtained: N-[5-(4-Fluoro-2- methyl-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide as a light-yellow viscous oil. ISN mass spectrum, m/e: 369 (M-I calculated for C 20 H 19 FN 2 O 2 S: 369).
  • Example 119 In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2- Chloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-3-trifluoromethyl-benzenesulfonamide as a light-brown viscous oil. ISN mass spectrum, m/e: 442.9 (M-I calculated for Ci 9 Hi 3 ClF 4 N 2 O 2 S: 443).
  • Example 120 In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2- Chloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-3
  • Example 122 a In analogy to example 1, on reaction of 5-(5-fluoro-2-methyl-phenyl)-pyridin-2- ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N- [5- (5- Fluoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a white solid.
  • Example 124 a In analogy to example 1, on reaction of 5-(5-fluoro-2-methyl-phenyl)-pyridin-2- ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro- N-[5-(5-fluoro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 389.1 (M- 1 calculated for C 19 H 16 ClFN 2 O 2 S: 389) .
  • Example 125 a In analogy to example 1, on reaction of 5-(5-chloro-2-methyl-phenyl)-pyridin-2- ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N- [5- (5- Chloro-2-methyl-phenyl)-pyridin-2-yl] -3-trifluoromethyl-benzenesulfonamide as an off- white solid.
  • Example 130 In analogy to example 1, on reaction of 5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin- 2-ylamine with 4-fiuoro-benzenesulfonyl chloride there was obtained: N- [5-(6-Chloro-2- fiuoro-3-methyl-phenyl)-pyridin-2-yl]-4-fiuoro-benzenesulfonamide as a light-yellow solid.
  • Example 132 a In analogy to example 1, on reaction of 5-(5-Chloro-2-methyl-phenyl)-6-methyl- pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(5- Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -4-fluoro-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 389 (M-I calculated for Ci 9 H 16 ClFN 2 O 2 S: 389).
  • Example 133 a In analogy to example 1, on reaction of 5-(5-Chloro-2-methyl- ⁇ henyl)-6-methyl- pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(5-chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl- benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 419 (M-I calculated for C 20 H 18 Cl2N 2 O 2 S: 419).
  • Example 134 a In analogy to example 1, on reaction of 5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6- methyl-pyridin-2-ylamine with 3-trifiuoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(6-Chloro-2-fiuoro-3-methyl-phenyl)-6-methyl-pyridin-2-yl]-3- trifluoromethyl-benzenesulfonamide as a light-yellow solid.
  • Example 142 a In analogy to example 1, on reaction of 5-(5-Fluoro-2-methyl-phenyl)-6-methyl- pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: 4-Fluoro- N-[5-(5-fluoro-2-methyl-phen7l)-6-methyl-pyridin-2-yl]-benzenesulfonamide as an off- white solid.
  • Example 143 a In analogy to example 1, on reaction of 5-(5-Fluoro-2-methyl-phenyl)-6-methyl- pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro- N- [5-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -benzenesulfonamide as an off- white solid. ISN mass spectrum, m/e: 389 (M-I calculated for C 19 H 16 ClFN 2 O 2 S: 389).
  • Example 144 a In analogy to example 1, on reaction of 5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2- ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N- [5-(2,5- Dichloro-phenyl)-6-methyl-pyridin-2-yl] -3-trifluoromethyl-benzenesulfonamide as an orange oil.
  • ISN mass spectrum, m/e: 459 (M-I calculated for C 19 H 13 Cl 2 F 3 N 2 O 2 S: 459).
  • Example 152 In analogy to example 1, on reaction of 5-(2 > 3-Dichloro-phenyl)-6-methyl-pyridin-2- ylamine with 3-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro- phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide as a white foam.
  • Example 153 a In analogy to example 1, on reaction of 5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2- ylamine with 2,4-dichloro-6-methyl-benzenesulfonyl chloride there was obtained: 2,4- Dichloro-N-[5-(2 ) 5-dichloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide as a light-yellow foam.
  • ISN mass spectrum, m/e: 475 (M-I calculated for Ci 9 H 14 Cl 4 F 3 N 2 O 2 S: 475).
  • Example 155 In analogy to example 1, on reaction of 5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin- 2-ylamine with 2,4-dichloro-5-methyl-benzenesulfonyl chloride there was obtained: 2,4- Dichloro-N- [5- (2-chloro-4-fluoro-phenyl) -6-methyl-pyridin-2-yl] -6-methyl- benzenesulfonamide as a white foam.
  • Example 158 In analogy to example 1, on reaction of 5-(2,4-bis-trifluoromethyl-phenyl)-pyridin-2- ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Bis- trifluoromethyl-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a white foam.
  • Example 167 a In analogy to example 1, on reaction of 5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2- ylamine with 3-trifluoro-benzenesulfonyl chloride there was obtained: N- [5-(2-Chloro- phenyl)-3,4-dimethyl-pyridin-2-yl] -3-t ⁇ ifluoromethyl-benzenesulfonamide as a yellow amorphous solid.
  • Example 168 a In analogy to example 1, on reaction of 5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2- ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2- chloro-phenyl)-3,4-dimethyl-pyridin-2-yl]-benzenesulfonamide as a yellow amorphous solid. ISN mass spectrum, m/e: 405.1 (M- 1 calculated for C 19 H 16 Cl 2 N 2 O 2 S: 405) .
  • Example 169 In analogy to example 1, on reaction of 5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2- ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2- chloro-phenyl)-3,4-dimethyl-pyridin-2-yl]-benzenes
  • Example 172 a In analogy to example 1, on reaction of 5-(2-Chloro-phenyl)-4-methyl-pyridin-2- ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2- Chloro-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as an off- white solid.
  • Example 174 In analogy to example 1, on reaction of 2-Methyl- [3,3']bipyridinyl-6-ylamine with 3- chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-(2-methyl- [3,3']bipyridinyl-6-yl)-benzenesulfonamide as a light-brown amorphous solid. ISN mass spectrum, m/e: 358 (M-I calculated for C 17 H 14 ClN 3 O 2 S: 358).
  • Example 176 a In analogy to example 1, on reaction of 5-(4-Fluoro-2-methyl-phenyl)-4-methyl- pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N- [5-(4-Fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 423 (M-I calculated for C 20 H 16 F 4 N 2 O 2 S: 423).
  • a compound of formula I can be used in a manner known per se as the active ingredient for the production of tablets of the following composition:
  • a compound of formula I can be used in a manner known per se as the active ingredient for the production of capsules of the following composition:

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R7, A, E and G have the significance given in claim 1 can be used in the form of pharmaceutical compositions. The compounds of formula (I) are useful as 11b-HSD1 inhibitors (T2D).

Description

Aryl-Pyridine Derivatives
The present invention is concerned with novel pyrimidine derivatives useful as llb- HSDl inhibitors (T2D).
The invention is concerned particularly with compounds of formula I
Figure imgf000002_0001
(0 and pharmaceutically acceptable salts and esters thereof, wherein
R1 is hydrogen, alkyl, cycloalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, amino or aminoalkyl;
R2 is hydrogen, alkyl or halogen;
R3 is hydrogen, alkyl or halogen;
R4 is phenyl, naphtyl, thiophenyl, pyridyl, quinolyl, piperidyl, morpholyl or thiomorpholyl optionally substituted with one or more substituents independently selected from alkyl, cycloalkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, cyano, trifluoromethyl, trifluoromethoxy, aryl, arylalkyl, aryloxy, heterocyclyl, alkylcarbonylamino, alkoxycarbonylalkoxy and alkyl-SO2- ; R5 is hydrogen or alkyl;
Figure imgf000003_0001
are independently selected from hydrogen, alkyl, halogen, cyano, trmuoromethyl, alkoxy ana all<yl-bϋ2-;
A is nitrogen or C-R10;
E is nitrogen or C-R9;
G is nitrogen or C-R8; and
wherein not more than one of A, E and G is nitrogen.
Glucocorticoids (Cortisol in humans, corticosterone in mice and rats) are an important class of adrenocorticosteroids that regulate many metabolic and homeostatic processes and form a key component of the response to stress. Glucocorticoids act via intracellular glucocorticoid receptors and, in some tissues, mineralocorticoid receptors; both being nuclear transcription factors. Glucocorticoid action on target tissues depends not only on circulating steroid concentrations and the cellular expression of receptors, but also on intracellular enzymes that critically determine to which extent glucocorticoids gain access to receptors in an active forms. 1 lbeta-hydroxysteroid dehydrogenases ( 1 lbeta- HSD's) catalyze the interconversion of the principal active 11 -hydroxy-glucocorticoid (Cortisol in men) and their inactive 11-keto metabolites (cortisone in men).
The enzyme 1 lbeta-hydroxysteroid dehydrogenase type 1 (llbeta-HSDl) inter- converts inactive into active glucocorticoids, thereby playing a major role in local modulation of cellular agonist concentration and thus activation of corticosteroid receptors in target tissues. Ih a recent study made by F. Hoffmann-La Roche differences in gene expression in lean and obese men were analyzed using gene array technology in order to identify specific changes in gene expression that might be associated with insulin resistance or altered metabolism. This study revealed that the mRNA for 1 lbeta-HSDl is approximately two-fold up regulated in adipose tissue in obese individuals. Moreover, overexpressing llbeta-HSDl in adipocytes of mice led to visceral obesity and to a syndrome-X like phenotype (Masuzaki H. et al., Science. 2001 Dec 7; 294(5549):2166-70.). Taken together, these data very strongly support an important role of llbeta-HSDl in the induction of obesity and the impairment of glucose homeostasis and lipid parameters. Thus, selective inhibition of this enzyme could lower blood glucose levels in Type 2 diabetic patients, normalize elevated lipid parameters and/or reduce weight in obese subjects .
The first pharmacological indication tnat llbeta-HSDi innibmon in men might have beneficial effects were obtained by using carbenoxolone, an anti-ulcer drug which inhibits both 1 lbeta-HSDl and the related enzyme 1 lbeta-HSD2. Treatment with carbenoxolone led to an increase in insulin sensitivity indicating that that inhibition of 1 lbeta-HSDl may reduce cellular Cortisol levels and therefore minimizing some of its deleterious effects. (Walker et al. 1995; J. Clin. Endocrinol. Metab. 80, 31155-3159).
1 lbeta-HSDl is expressed in many tissues including liver, adipose tissue, vascular smooth muscles, pancreas and brain. Its activity is dependent on NADP(H) and it has a relatively low affinity for its substrate (compared to llbeta-HSD2). 11 beta-HSDl in tissue homogenates and when purified is bidirectional, exhibiting both 1 lbeta-dehydrogenase and llbeta-reductase reactions, with greater stability of the dehydrogenase activity (P.M. Stewart and Z.S. Krozowski, Vitam. Horm. 57 (1999), pp. 249-324). However, when the enzyme activity is tested in intact cells, the 1 lbeta-reductase activity predominates, which regenerates active glucocorticoids from inert 11-keto forms. Such glucocorticoid regeneration will increase effective intracellular glucocorticoid levels and thereby amplifying glucocorticoid activity. It is this elevated cellular Cortisol concentration that might lead to increased hepatic glucose production, adipocyte differentiation and insulin resistance.
Inhibition of 1 lbeta-HSDl should not only reduce the typical Syndrome-X / Diabetes associated symptoms, but it should also be save and without major side effect. Studies with the unspecific inhibitor carbenoxolone highlight the importance of developing specific 1 lbeta-HSDl inhibitors. The inhibition of the llbeta-HSD2 enzyme is badly tolerated and results in increased blood pressure. In contrast inhibition of 1 lbeta- HSDl should be well tolerated since 1 lbeta-HSDl knockout mice were found be healthy and to resist hyperglycemia provoked by obesity or stress (Kotelevtsev Y. et al., Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14924-9). Similar upon starvation these mice had attenuated activation of key hepatic enzymes that are involved in gluconeogenesis. In addition, these mice had improved lipid and lipoprotein profiles suggesting that inhibition of HSDl might be highly efficacious and safe. Recent reports indicate that 1 lbeta-HSDl inhibitors might also be beneficial to reduce high blood pressure (Masuzaki H. et al., J Clin Invest. 2003 July;112(l):83-90; Rauz S. et al., QJM. 2003 July;96(7):481-90) to improve cognition (Sandeep TC. et al., Proc Natl Acad Sci U S A. 2004 Apr. 27;101(17):6734-9) or to improve Alzheimer associated deficits. Taken together llbeta-HSDl inhibition might be a save and efficacious approach to treat symptoms of diabetes, obesity and other diseases.
The compounds of formula I and their pharmaceutically acceptable salts and esters are novel and have valuable pharmacological properties. In particular they are 1 Ib-HSDl inhibitors (T2D) and they display selectivity against the related llbeta-HSD2 enzyme. Therefore the compounds which are specific llbeta-HSDl inhibitors (T2D) represent an approach to e.g. lower blood glucose levels and normalize lipid parameters in Type 2 diabetic patients by modulating the local concentration of the active glucocorticoid Cortisol in target tissue (liver, adipose tissue).
The compounds of the present invention can be used in the prophylaxis and/or treatment of metabolic disorders, obesity, dyslipidemiae, hypertension and/or diabetes, particularly diabetes Type II.
The compounds of this invention can further be used in the prophylaxis and/or treatment of high ocular eye pressure, cognition, Alzheimer and/or neurodegeneration.
Objects of the present invention are the compounds of formula I and their aforementioned salts and esters per se and their use as therapeutically active substances, a process for the manufacture of the said compounds, intermediates, pharmaceutical compositions, medicaments containing the said compounds, their pharmaceutically acceptable salts and esters, the use of the said compounds, esters and salts for the prophylaxis and/or therapy of illnesses, especially in the treatment or prophylaxis of eating disorders, obesity, dyslipidemiae, hypertension and/or diabetes, particularly diabetes Type II, and the use of the said compounds, salts and esters for the production of medicaments for the treatment or prophylaxis of metabolic disorders, obesity, dyslipidemiae, hypertension and/or diabetes, particularly diabetes Type II.
The compounds of the present invention can further be combined with PPAR (alpha, gamma, delta) agonists, DHEA (dehydroepiandrosterone), DPPIV inhibitors, insulin and/or lipase inhibitors, particularly orlistat.
In the present description the term "alkyl", alone or in combination, signifies a straight-chain or branched-chain alkyl group with 1 to 8 carbon atoms, preferably a straight or branched-chain alkyl group with 1 to 6 carbon atoms and particularly preferred a straight or branched-chain alkyl group with 1 to 4 carbon atoms Examples of straight- chain and branched C1-C8 alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert. -butyl, the isomeric pentyls, the isomeric hexyls, the isomeric heptyls and the isomeric octyls, preferably methyl and ethyl and most preferred methyl.
The term "cycloalkyl", alone or in combination, signifies a cycloalkyl ring with 3 to 8 carbon atoms and preferably a cycloalkyl ring with 3 to 6 carbon atoms. Examples of C3-C8 cycloalkyl are cyclopropyl, methyl-cyclopropyl, dimethylcydopropyl, cyclobutyl, methyl- cyclobutyl, cydopentyl, methyl-cyclopentyl, cyclohexyl, methyl- cydohexyl, dimethyl- cyclohexyl, cycloheptyl and cyclooctyl, preferably cyclopropyl.
The term "alkoxy", alone or in combination, signifies a group of the formula alkyl-
O- in which the term "alkyl" has the previously given significance, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec. butoxy and tert.butoxy, preferably methoxy and ethoxy and most preferred methoxy.
The term "hydroxyalkyl", alone or in combination, signifies an alkyl group as defined before, wherein one or more hydrogen atoms, preferably one hydrogen atom is replaced by a hydroxy group. Examples of hydroxyalkyl are hydroxymethyl and hydroxyethyl.
The term "aryl", alone or in combination, signifies a phenyl or naphthyl group, preferably a phenyl group which optionally carries one or more substituents, preferably one to three, each independently selected from halogen, trifluorornethyl, trifluoromethoxy, amino, alkyl, alkoxy, alkylcarbonyl, cyano, carbamoyl, alkoxycarbamoyl, methylendioxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkyaminocarbonyl, dialkylaminocarbonyl, hydroxy, nitro, alkyl-SO2-, amino-SO2-, cycloalkyl and the like. Preferred is phenyl or naphthyl, particularly phenyl optionally substituted with one to three, preferably one or two substituents independently selected from alkyl, halogen, alkoxy, trifluoromethoxy, nitro and trifluoromethyl. Particularly preferred is phenyl.
The term "aryloxy", alone or in combination, signifies a aryl-O- group in which the term "aryl" has the previously given significance.
The term "heterocyclyl", alone or in combination signifies a saturated, partially unsaturated or aromatic 5- to 10-membered heterocycle which contains one or more hetero atoms selected from nitrogen, oxygen and sulphur. If desired, it can be substituted on one or more carbon atoms e.g. by halogen, alkyl, alkoxy, oxo etc. and/or on a secondary nitrogen atom (i.e. -NH-) by alkyl, cycloalkyl, aralkoxycarbonyl, alkanoyl, phenyl or phenylalkyl or on a tertiary nitrogen atom (i.e.=N-) by oxido, with halogen, alkyl, cycloalkyl and alkoxy being preferred. Examples of such heterocyclyl groups are pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyrazoyl, imidazoyl (e.g. imidazol-4-yl and 1-benzyloxycarbonyl- imidazol-4-yl), pyrazoyl, pyridyl, pyrazinyl, pyrimidinyl, hexahydro-pyrimidinyl, furyl, thienyl, thiazolyl, oxazolyl, indolyl (e.g. 2- indolyl), quinolyl (e.g. 2-quinolyl, 3-quinolyl and l-oxido-2-quinolyl), isoquinolyl (e.g. 1- isoquinolyl and 3-isoquinolyl), tetrahydroquinolyl (e.g.l,2>3,4-tetrahydro-2-quinolyl), 1,2,3,4-tetrahydroisoquinolyl (e.g. 1,2,3,4-tetrahydro-l-oxo-isoquinolyl) and quinoxalinyl. Preferred examples are thiophenyl, quinolyl, piperidyl, morpholyl, thiomorpholyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazolyl, imidazolyl and thiazolyl.
The term "amino", alone or in combination, signifies a primary, secondary or tertiary amino group bonded via the nitrogen atom, with the secondary amino group carrying an alkyl or cycloalkyl substituent and the tertiary amino group carrying two similar or different alkyl or cycloalkyl substituents or the two nitrogen substitutents together forming a ring, such as, for example, -NH2, methylamino, ethylamino, dimethylamino, diethylamino, methyl-ethylamino, pyrrolidin-1-yl or piperidino etc., preferably primary amino, dimethylamino and diethylamino and particularly dimethylamino.
The term "halogen", alone or in combination, signifies fluorine, chlorine, bromine or iodine and preferably fluorine, chlorine or bromine.
The term "carbonyl", alone or in combination, signifies the -C(O)- group.
The term "oxy", alone or in combination, signifies the -O- group.
The term "nitro", alone or in combination signifies the -NO2 group.
The term "cyano", alone or in combination signifies the group -CN.
The term "pharmaceutically acceptable salts" refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable. The salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, preferably hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxylic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcystein and the like. In addition these salts maybe prepared form addition of an inorganic base or an organic base to the free acid. Salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like. Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polymine resins and the like. The compound of formula I can also be present in the form of zwitterions. Particularly preferred pharmaceutically acceptable salts of compounds of formula I are the hydrochloride salts.
The compounds of formula I can also be solvated, e.g. hydrated. The solvation can be effected in the course of the manufacturing process or can take place e.g. as a consequence of hygroscopic properties of an initially anhydrous compound of formula I (hydration). The term pharmaceutically acceptable salts also includes physiologically acceptable solvates.
"Pharmaceutically acceptable esters" means that compounds of general formula (I) maybe derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compounds in vivo. Examples of such compounds include physiologically acceptable and metabolically labile ester derivatives, such as methoxymethyl esters, methylthiomethyl esters and pivaloyloxymethyl esters. Additionally, any physiologically acceptable equivalents of the compounds of general formula (I), similar to the metabolically labile esters, which are capable of producing the parent compounds of general formula (I) in vivo, are within the scope of this invention.
The compounds of formula I can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereioisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates.
Preferred are the compounds of formula I and pharmaceutically acceptable salts thereof, particularly the compounds of formula I. Further preferred are compounds of formula I, wherein R1 is hydrogen. Also preferred are compounds of formula I, wherein R1 is alkyl, preferably methyl.
Another preferred object of the present invention are the compounds of formula I, wherein R2 is hydrogen. Further preferred are those compounds according to formula I, wherein R2 is alkyl. Particularly preferred are those compounds of formula I, wherein R2 is methyl.
Also preferred are the compounds of formula I, wherein R3 is hydrogen. Further preferred are those compounds according to formula I, wherein R3 is alkyl.
Another preferred aspect of the present invention are compounds of formula I, wherein R5 is hydrogen.
Particularly preferred are those compounds of formula I, wherein A is C-R10. Further preferred are those compounds of formula I, wherein A is nitrogen.
Preferred are those compounds of formula I, wherein E is C-R9. Further preferred are those compounds of formula I, wherein E is nitrogen.
Another preferred aspect of the present invention are the compounds of formula I, wherein G is C-R8. Also preferred are those compounds of formula I, wherein G is nitrogen.
Preferred are the compounds of formula I, wherein R4 is phenyl, naphtyl, thiophenyl, pyridyl, quinolyl, piperidyl, morpholyl or thiomorpholyl optionally substituted with one to three, preferably one or two substituents independently selected from alkyl, cycloalkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, cyano, trifluoromethyl, trifluoromethoxy, aryl, arylalkyl, aryloxy, heterocyclyl, alkylcarbonylamino, alkoxycarbonylalkoxy and alkyl-SO2- .
Further preferred are compounds of formula I, wherein R is phenyl optionally substituted with one to three substituents independently selected from alkyl, cycloalkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, cyano, trifluoromethyl, trifluoromethoxy, aryl, arylalkyl, aryloxy, heterocyclyl, alkylcarbonylamino, alkoxycarbonylalkoxy and alkyl-SO2-. Particularly preferred are those compounds of formula I, wherein R4 is phenyl substituted with one to three substituents independently selected from alkyl, halogen and trifluoromethyl.
Preferred are compounds of formula I, wherein R6, R7, R8, R9 and R10 are independently selected from hydrogen, alkyl, halogen and trifluoromethyl.
Particularly preferred are those compounds of formula I, wherein R6 is halogen, alkyl or trifluoromethyl. Especially preferred are those compounds of formula I, wherein R6 is chloro, methyl or trifluoromethyl.
Examples of preferred compounds of formula (I) are:
1. N- [5-(2-Chloro-phenyl)-pyridin-2-yl] -5-fluoro-2-methyl-benzenesulfonamide;
2. 3-Chloro-N- [5-(2-chloro-phenyl)-pyridin-2-yl] -2-methyl-benzenesulfonamide;
3. N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
4. 4a) 3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2-methyl- benzenesulfonamide; 4b) 3-Chloro-N- [5-(2-chloro-phenyl)-6-methyl-pyridin-2- yl] -2-methyl-benzenesulfonamide;
5. Biphenyl-4-sulfonic acid [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-amide;
6. 3-Chloro-N-[5-(2-chloro-4-fluoro-phenyl)-pyridin-2-yl]-2-methyl- benzenesulfonamide;
7. 3-Chloro-N-[5-(3-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
8. 3-Chloro-N- [5-(2,4-difIuoro-phenyl)-pyridin-2-yl] -2-methyl-benzenesulfonamide;
9. N- [5-(2,4-Difiuoro-phenyl)-pyridin-2-yl] -5-fluoro-2-methyl-benzenesulfonamide;
10. 3-Chloro-N-[5-(4-methox7-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
11. 3-Chloro-N-[5-(4-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
12. 5-Fluoro-N- [5- (4-fluoro-phenyl) -pyridin-2-yl] -2-methyl-benzenesulfonamide;
13. 5-Fluoro-N- [5- (2-methox7-phenyl) -pyridin-2-yl] -2-methyl-benzenesulfonamide; 14. 3-Chloro-N-[5-(2-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
15. 5-Fluoro-N- [5-(2-fluoro-phenyl)-pyridin-2-yl] -2-methyl-benzenesulfonamide;
16. 2,4-Dichloro-N- [5-(2-chloro-phenyl)-pyridin-2-yl] -6-methyl-benzenesulfonamide;
17. N- [5-(2-Chloro-phenyl)-pyridin-2-yl] -2,5-difluoro-benzenesulfonamide;
18. 3-Chloro-N-[5-(4-methanesulfonyl-phenyl)-pyridin-2-yl]-2-methyl- benzenesulfonamide;
19. 3-Chloro-N- [5-(4-fluoro-phenyl)-6-methyl-pyτidin-2-yl] -2-methyl- benzenesulfonamide;
20. 5-Fluoro-N- [5-(4-fluoro-phenyl)-6-methyl-pyτidin-2-yl] -2-methyl- benzenesulfonamide;
21. 3-Chloro-N- [5- (3-fluoro-phenyl)-6-methyl-pyridin-2-yl] -2-methyl- benzenesulfonamide;
22. 5-Fluoro-N- [5-(3-fluoro-phenyl)-6-methyl-pyridin-2-yl] -2-methyl- benzenesulfonamide;
23. N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-3,4-dimethoxy-benzenesulfonamide;
24. 3,4-Dichloro-N- [5-(2,4-dichloro-phenyl)-pyridin-2-yi] -benzenesulfonamide;
25. N- [5-(2,3-Dichloro-phenyl)-pyridin-2-yl] -2,5-difluoro-benzenesulfonamide;
26. 3-Chloro-N-[5-(2,3-dichloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
27. 3,4-Dichloro-N- [5-(2-chloro-phenyl)-pyridin-2-yl] -benzenesulfonamide;
28. N- [5-(2-Chloro-phenyl)-pyridin-2-yl] -3,4-dimethoxy-benzenesulfonamide;
29. 3-Chloro-N- [5-(2-chloro-phenyl)-pyridin-2-yl] -4-methyl-benzenesulfonamide;
30. 5-Fluoro-N- [5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl] -2-methyl- benzenesulfonamide; - • ω j aj
- 11 -
31. 3-Chloro-N- [5- (4-fluoro-2-methyl-phenyl)-pyridin-2-yl] -2-methyl- benzenesulfonamide;
32. 3-Chloro-N- [5-(2-chloro-phenyl)-pyridin-2-yl] -4-methoxy-benzenesulfonamide;
33. 4,5-Dichloro-N- [5-(2-chloro-phenyl)-pyridin-2-yl] -2-fluoro-benzenesulfonamide;
34. 3-Chloro-N- [5-(2,4-dichloro-phenyl)-pyridin-2-yl]-4-met±ιoxy- benzenesulfonamide;
35. 3-Chloro-N- [5-(2,4-dichloro-phenyl)-pyridin-2-yl] -4-methyl-benzenesulfonamide;
36. Piperidine-1 -sulfonic acid [5-(2>4-dichloro-phenyl)-pyridin-2-yl]-amide;
37. N- [5-(2,3-Dichloro-phenyl)-pyridin-2-yl] -2-trifluoromethyl-benzenesulfonamide;
38. N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
39. N-[5-(2,5-Dichloro-phenyl)-pyridin-2-yl]-2,5-difluoro-benzenesulfonamide;
40. N-[5-(2,5-Dichloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
41. 3-Chloro-N- [5-(2J5-dichloro-phenyl)-pyridin-2-yl] -2-methyl-benzenesulfonamide;
42. 5-Fluoro-N-[5-(2-fluoro-5-trifluoromethyl-phenyl)-pyridin-2-yl]-2-methyl- benzenesulfonamide;
43. 3-Chloro-N- [5-(2-fluoro-5-trifluoromethyl-phenyl)-pyridin-2-yl] -2-methyl- benzenesulfonamide;
44. 3-Chloro-2-methyl-N- [5-(2-trifluoromethyl-phenyl)-pyridin-2-yl] - benzenesulfonamide;
45. 3-Chloro-4-methyi-N- [5-(2-trifluoromethyl-phenyl)-pyridin-2-yl] - benzenesulfonamide;
46. 5-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl] -2-methoxy- benzenesulfonamide;
47. N-{2-Chloro-4- [5-(2,4-dichloro-phenyl)-pyridin-2-ylsulfamoyl] -phenyl}- acetamide; 48. N- [5-(2,4-Dichloro-phenyl)-pyridin-2-yl] -4-trifluoromethyl-benzenesulfonamide;
49. N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-methysιilfonyl-benzenesulfonamide;
50. 3-Chloro-N- [5-(2,3-difluoro-phenyl)-pyridin-2-yl] -4-rnethyl-benzenesulfonamide;
51. N-[5-(2,3-Difluoro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
52. N- [5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl] -3-chloro-2-methyl- benzenesulfonamide;
53. N- [5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl] -3-chloro-4-methyl- benzenesulfonamide;
54. 3-Chloro-N- [5- (2,3-difluoro-phenyl) -pyridin-2-yl] -2-methyl-benzenesulfonamide;
55. Piperidine-1 -sulfonic acid [5-(2,3-dichloro-phenyl)-pyridin-2-yl]-amide;
56. 5-Chloro-N- [5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl] -2-methoxy- benzenesulfonamide;
57. N-{2-Chloro-4- [5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylsulfamoyl] -phenyl}- acetamide;
58. N-[5-(4-Fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-txifluoromethyl- benzenesulfonamide;
59. N-[5-(4-Fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-methanesulfonyi- benzenesulfonamide;
60. {4-[5-(2,3-Dichloro-phenyl)-pyridin-2-ylsulfamoyl]-phenoxy}-acetic acid methyl ester;
61. N-[5-(4-Fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethox^- benzenesulfonamide;
62. 3-Chloro-N- [5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl] -4-methoxy- benzenesulfonamide;
63. 4-Chloro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2,5-dimethyl- benzenesulfonamide; 64. N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-(2-hydroxy-ethoxy)- benzenesulfonamide;
65. N- [5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl] -4-fluoro-benzenesulfonamide;
66. 3-Chloro-N- [5-(2-chloro-phenyl)-6-met±iyl-pyridin-2-yl] -4-methyl- benzenesulfonamide;
67. 4-Chloro-N- [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl] -benzenesulfonamide;
68. 2,4-Dichloro-N- [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl] -6-methyl- benzenesulfonamide;
69. Piperidine-1 -sulfonic acid [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-amide;
70. N- [5-(2,4-Dichloro-phenyl)-pyτidin-2-yl] -4-fluoro-benzenesulfonamide;
71. 4-Chloro-N- [5-(2,4-dichloro-phenyl)-pyridin-2-yl] -2,5-dimethyl- benzenesulfonamide;
72. N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
73. 2,4-Dichloro-N- [5-(2,4-dichloro-phenyl)-pyridin-2-yl] -5-methyl- benzenesulfonamide;
74. N- [5-(2,3-Dichloro-phenyl)-pyridin-2-yl] -3-trifluoromethyl-benzenesulfonamide
75. 4-Fluoro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyτidin-2-yl]- benzenesulfonamide;
76. 3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl- benzenesulfonamide;
77. 5-Fluoro-N- [5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -2-methyl- benzenesulfonamide;
78. 3-Chloro-N- [5-(2,3-dichloro-phenyl)-pyridin-2-yl] -4-methyl-benzenesulfonamide;
79. N- [5- (2,3-Dichloro-phenyl) -pyridin-2-yl] -4-trifluoromethyl-benzenesulfonamide; 80. 3-Chloro-N- [5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl] -4-methyl- benzenesulfonamide;
81. N- [5-(4-Fluoro-2-methyl-phenyl)-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
82. N- [5-(4-Fluoro-2-methyl-phenyl)-pyridin-2-yl] -4-trifluoromethyl- benzenesulfonamide;
83. N- [5-(2-Chloro-phenyl)-pyridin-2-yl] -3-trifluoromethyl-benzenesulfonamide;
84. N- [5-(2-Chloro-phenyl)-pyτidin-2-yl] -4-ethyl-benzenesulfonamide;
85. 3-Chloro-N- [5-(2-chloro-phenyl)-pyridin-2-yl] -benzenesulfonamide;
86. 3-Chloro-N- [5-(2)4-dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
87. N- [5-(2,4-Dichloro-phenyl)-pyridin-2-yl] -4-ethyl-benzenesulfonamide;
88. N- [5-(2,4-Dichloro-phenyl)-pyridin-2-yl] -3-trifluoromethyl-benzenesulfonamide;
89. N- [ 5- (2-Chloro-phenyl) -6-methyl-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
90. N- [5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl] -4-trifluoromethoxy- benzenesulfonamide;
91. N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
92. N- [5-(2-Chloro-phenyl)-pyridin-2-yl] -2,4-difluoro-benzenesulfonamide;
93. 4-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide;
94. 4-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yi]-2,5-dimethyl- benzenesulfonamide;
95. N- [5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl] -2,4-difluoro-benzenesulfonamide;
96. 3,5-Dichloro-N- [5-(2-chloro-phenyl)-6-methyl-pyτidin-2-yl] -benzenesulfonamide; 97. N-[5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide;
98. N- [5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl] -4-fluoro-benzenesulfonamide;
99. N- [5-(2,4-Dichloro-ρhenyl)-6-methyl-pyridin-2-yl] -2,4-difluoro- benzenesulfonamide;
100. 4-Chloro-N- [5-(2,4-dichloro-phenyl)-6-methyl-pyridin-2-yl] -2,5-dimethyl- benzenesulfonamide;
101. 2,4-Dichloro-N- [5-(2,4-dichloro-phenyl)-pyridin-2-yl] -6-methyl- benzenesulfonamide;
102. 3-Chloro-N- [5-(2,4-dichloro-phenyl)-pyridin-2-yl] -benzenesulfonamide;
103. 4-Chloro-N[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-benzenesulfonamide;
104. N-[5-(2-Chloro-pb.enyl)-6-methyl-pyridin-2-yl]-3-fluoro-benzenesulfonamide;
105. 3-Chloro-N- [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl] -benzenesulfonamide;
106. 2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
107. 2,4-Dichloro-N- [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl] -5-methyl- benzenesulfonamide;
108. N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide;
109. 2,4-Dichloro-N- [5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -6-methyl- benzenesulfonamide;
110. 3-Chloro-N- [5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] - benzenesulfonamide;
111. 4-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]- benzenesulfonamide;
112. N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethox7- benzenesulfonamide; 113. N- [5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -3-methyl- b enzenesulfonamide;
114. 2-Chloro-N- [5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -5- trifluoromethyl-benzenesulfonamide;
115. 4-Fluoro-N- [5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -3- trifluoromethyl-benzenesulfonamide;
116. N- [5- (2-Chloro-phenyl) -6-methyl-pyridin-2-yl] -3-methyl-benzenesulfonamide;
117. 3-Chloro-N-(2-chloro-phenyl)-6-methyl-pyridin-2-yl] -4-fluoro- benzenesulfonamide;
118. 2-Chloro-N- [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl] -5-trifluoromethyl- benzenesulfonamide;
119. N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-3-trifluoromethyl- benzenesulfonamide;
120. N- [5-(2,3-Dichloro-phenyl)-pyridin-2-yl] -3-fluoro-4-methyl-benzenesulfonamide;
121. N-[5-(2)3-Dichloro-phenyl)-pyridin-2-yl]-3,5-dimethyl-benzenesulfonamide;
122. N- [5-(5-Fluoro-2-methyl-phenyl)-pyridin-2-yl] -3-trifluoromethyl- benzeπesulfonamide;
123. 4-Fluoro-N-[5-(5-fluoro-2-methyl-phenyl)-pyridin-2-yl]-benzenesulfonamide;
124. 3-Chloro-N-[5-(5-fluoro-2-methyl-phenyl)-pyτidin-2-yl]-2-methyl- benzenesulfonamide;
125. N- [5-(5-Chloro-2-methyl-phenyl)-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
126. N- [5-(5-Chloro-2-methyl-phenyl)-pyridin-2-yl] -4-fluoro-benzenesulfonamide;
127. 3-Chloro-N- [5-(5-chloro-2-methyi-phenyl)-pyridin-2-yl] -2-methyl- benzenesulfonamide; 128. 3-Chloro-N- [5-(6-chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl] -2-methyl- benzenesulfonamide;
129. N- [5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
130. N- [5-(6-Chloro-2-fluoro-3-methyl-pheπyl)-pyridin-2-yl] -4-fluoro- benzenesulfonamide;
131. N-[5-(5-Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide;
132. N- [5-(5-Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -4-fluoro- benzenesulfonamide;
133. 3-Chloro-N- [5-(5-chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -2-methyl- benzenesulfonamide;
134. N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6-methyl-pyridin-2-yl]-3- trifluoromethyl-benzenesulfonamide;
135. N- [5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6-raethyl-pyridin-2-yl] -4-fluoro- benzenesulfonamide;
136. 4-Chloro-N- [5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl] -benzenesulfonamide;
137. 3-Chloro-N- [5-(4-fluoro-2-methyl-phenyl)-ρyridin-2-yl] -benzenesulfonamide;
138. 2,4-Dichloro-N- [5-(4-fluoro-2-methyl-ph.enyl)-pyridin-2-yl] -6-methyl- benzenesulfonamide;
139. 3-Chloro-N-[5-(2,5-dichloro-phenyl)-6-methyl-pyridin-2-yl] -benzenesulfonamide;
140. N- [5-(2,5-Dichloro-phenyl) -6-methyl-pyridin-2-yl] -4-fluoro-benzenesulfonamide;
141. N- [5-(5-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
142. 4-Huoro-N- [5-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] - benzenesulfonamide; 143. 3-Chloro-N- [5-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] - benzenesulfonamide;
144. N-[5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide;
145. N- [5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
146. N- [5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl] -4-fluoro- benzenesulfonamide;
147. 3-Chloro-N-[5-(2-chloro-4-fluoro-phenyl)-6-methyl-pyτidin-2-yl]- benzenesulfonamide;
148. N- [5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
149. N- [5-(2>3-Dichloro-phenyl)-6-methyl-pyridin-2-yl] -4-fluoro-benzenesulfonamide;
150. 3-Chloro-N- [5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl] -benzenesulfonamide;
151. 2,4-Dichloro-N- [5- (2,3-dichloro-phenyl) -6-methyl-pyridin-2-yl] -6-methyl- benzenesulfonamide;
152. N- [5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl] -3-methyl-benzenesulfonamide;
153. 2,4-Dichloro-N-[5-(2,5-dichloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide;
154. N-[5-(2-Chloro-4-fiuoro-phenyl)-6-methyl-pyridin-2-yl]-3-methyl- benzenesulfonamide;
155. 2,4-Dichloro-N- [5-(2-chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl] -6-methyl- benzenesulfonamide;
156. N- [5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl] -3-chloro-benzenesulfonamide;
157. N- [5- (2,4-Bis-trifluoromethyl-phenyl) -pyridin-2-yl] -3-methyl-benzenesulfonamide;
158. N- [5-(2,4-Bis-trifluoromethyi-phenyi)-pyridin-2-yl] -4-fluoro-benzenesulfonamide; 159. N-[5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-3-trifluoromethyl- benzenesulfonamide;
160. 3-Chloro-N- [5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl] -4-fluoro- benzenesulfonamide;
161. 3-Chloro-N- [5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl] -benzenesulfonamide;
162. 4-Fluoro-N-[ 5- (2-fluoro-phenyl)-6-methyl-pyridin-2-yl] -benzenesulfonamide;
163. 4-Fluoro-N- [5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
164. N- [5-(2,4-Bis-txifluoromethyl-phenyl)-pyridin-2-yl] -3-chloro-4-fluoro- benzenesulfonamide;
165. 2,4-Dichloro-N- [5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl] -6-methyl- benzenesulfonamide;
166. N- [5-(2-Fluoro-phenyl)-6-methyl-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
167. N- [5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2-yl] -3-trifiuoromethyl- benzenesulfonamide;
168. 3-Chloro-N- [5- (2-chloro-phenyl) -3,4-dimethyl-pyridin-2-yl] -benzenesulfonamide;
169. N- [5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2-yl] -4-fluoro-benzenesulfonamide;
170. N-(2-Methyl-[3,3']bipyridinyl-6-yl)-3-trifluoroniethyl-benzenesulfonamide;
171. 3-Chloro-N-[5-(2-chloro-phenyl)-4-methyl-pyridin-2-yl]-benzenesulfonamide;
172. N-[5-(2-Chloro-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide;
173. 2,4-Dichloro-N-[5-(2-chloro-phenyl)-4-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide;
174. 3-Chloro-N- (2-methyl- [3,3']bipyridinyl-6-yl)-benzenesulfonamide; 175. 3-Chloro-N- [5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl] - benzenesulfonamide;
176. N-[5-(4-Fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyi- benzenesulfonamide; and
177. 2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide.
Examples of particularly preferred compounds of formula (I) are:
N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
3-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide;
4,5-Dichloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2-fluoro-benzenesulfonamide;
3-Chloro-N-[5-(2,4-dichloro-phenyi)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
Piperidine-1 -sulfonic acid [5-(2,4-dichloro-phenyl)-pyridin-2-yl]-amide;
N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
3-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-4-methyl-benzenesulfonamide;
4-CUoro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide;
N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
N-[5-(2)4-Dichloro-phenyl)-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-meth.yl-pyridin-2-yl]-2-methyl- benzenesulfonamide; 3-Chloro-N-[5-(2J3-dichloro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
3-CUoro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
N-[5-(4-Fluoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
N- [5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl] -3-trifluoromethyl-benzenesulfonamide;
N- [5-(2-Chloro-phenyl)-pyridin-2-yl] -4-fluoro-benzenesulfonamide;
N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
N-[5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
2,4-Dichloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide;
2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yi]-benzenesulfonamide;
N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide;
3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
N-[5-(4-Fluoro-2-meώyl-phenyl)-6-methyl-pyridin-2-yl]-3-rnethyl-benzenesιilfonamide;
N- [5-(5-Fluoro-2-methyl-phenyl)-pyridin-2-yl] -3-trifluoromethyl-benzenesulfonamide;
N-[5-(5-CWoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenestιlfonainide;
N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl] -4-fluoro-benzenesulfonamide;
3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl] -benzenesulfonamide;
2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-6-methyl- benzenesulfonamide;
4-Fluoro-N- [5- (5-fluoro-2-methyl-phenyl) -6-methyl-pyridin-2-yl] -benzenesulfonamide;
N-[5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide; 24-Dichloro-N-[5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide;
2,4-Dichloro-N-[5-(2-chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide;
N- [5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl] -3-chloro-benzenesulfonamide;
3-Chloro-N-[5-(2-chloro-phenyl)-4-methyl-pyridin-2-yl]-benzenesulfonamide;
N-[5-(2-Chloro-phenyl)-4-inethyi-pyridin-2-yl]-3-trifluoromethyi-benzenesulfonamide;
3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl] -benzenesulfonamide;
N-[5-(4-Fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide; and
2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyτidin-2-yl]-6-methyl- benzenesulfonamide.
Processes for the manufacture of compounds of formula I are an object of the invention.
The preparation of compounds of formula I of the present invention maybe carried out in sequential or convergent synthetic routes. Syntheses of the invention are shown in the following Schemes. The skills required for carrying out the reaction and purification of the resulting products are known to those in the art. The substituents and indices used in the following description of the processes have the significance given above unless indicated to the contrary.
Compounds of general formula I can be obtained according to scheme 1 from compounds of formula II comprising R1 to R7 substituents and A, E, G definitions according to the above description via a condensation reaction with aryl, heteroaryl or heterocydyl sulfonyl chlorides, in the presence of a base such as trietylamine or (4- dimetylamino) -pyridine (DMAP) in a solvent such THF, ethanol, methylene chloride DMF or DMSO, or in pyridine as a solvent, with or without the addition of a base such as trietylamine or DMAP, at room temperature or at elevated temperatures, to give compounds of general formula I. Compounds of formula I where R5 equals alkyl can also be prepared from compounds of formula I where R5 equals H via an alkylation reaction, using, for example, NaH as a base and DMF as solvent, at room temperature or at elevated temperatures.
Figure imgf000024_0001
Alternatively, compound of general formula I can be prepared according to scheme 2 from compounds of general formula III in a substitution reaction with an corresponding aryl heteroaryl or heterocyclyl sulphonamide, in the presence of a base such as sodium hydride, Na2CO3 or triethyl amine and in a solvent such as THF, DMF or DMSO at room temperature or at elevated temperatures. The reaction can also be carried out under the condition of an Ullman-type reaction with, for example Cu(I) chloride, or Cu(I) iodide in a solvent such as dioxane or DMF, in analogy to a method described by S. L. Buchwald (J. Am. Chem. Soc, 2001, 7727).
Figure imgf000024_0002
0)
A further alternative consists of reacting compounds of general formula IV via a metal- catalysed (Pd or Ni) cross-coupling reaction with corresponding organometallic reagent such as (hetero)arylboron, (hetero)arylzink or (hetero)aryltin reagents using Suzuki-, Stille- or Negishi-type coupling reactions (for literature: Suzuki, Chem. Rev., 1995, 95, 2475; Stifle, Angew. Chem. IEE, 1986, 25, 508; Negishi, Ace. Chem. Res., 1982, 15, 340).
Scheme 3
Figure imgf000025_0001
M: B(OH)2, SnR3 Or ZnBr
Intermediated II, III and IV are either commercial available, known in the literature or can be prepared by applying a sequence of standard reactions known in the art and outlined in scheme 4. Thus, starting from appropriate 2-pyridones of formula V, which are either known in the literature or can be prepared according to standard procedures, subsequent halogenation with POC13.PC13 or POBr3 gives rise to the corresponding 2-chloro or 2- bromo pyridines of formula VI. The iodo derivatives can be obtained from the chloro or bromo derivatives via halogen exchange with NaI (for general reaction of this type: R.C. Corcoran, Tetrahedron Lett. 1990, p6757). Subsequent reaction with alkyl amines or ammonia, either applied in access, without solvent, or in equimolar amounts, in a suited solvent such as ethanol, water, DMF or THF, gives rise to compounds of formula VII. The reaction can also be performed in an autoclave at elevated pressure in analogy to published procedures (for an example: T. Haga, Heterocyles, 22, pi 17).
Scheme 4
Figure imgf000026_0001
Compounds of formula II can then be be prepared from VII via a metal- catalysed (Pd or Ni) cross-coupling reaction with corresponding organometallic reagent such as (hetero)arylboron, (hetero)arylzink or (hetero)aryltin reagents using Suzuki-, Stille- or Negishi-type coupling reactions as descibed above. The amino group can optionally be protected with standard protecting groups such as BOC or pivaloyl prior to performing the cross-coupling reaction. Compounds of formula III are obtained from compounds of formula VIII (prepared from V via metal-catalysed cross-coupling as for II) by an halogenation reaction (as for the preparation of VI). Compounds of formula IV can be prepared from VI via a nudeophilic substitution reaction with a corresponding aryl, heteroayryl or heterocycylyl sulfonamide in a solvent such as DMSO or DMF in the presence of a base such as sodium hydride, at room temperature or at elevated temperature. The sulfonamides used in this step are either commercial, known in the literature or can be obtained by standard procedures known in the art. They can also first be converted into their sodium or potassium and these salts can then be used in the reaction, a procedure which does not require the addition of further base. Alternatively, IV can be obtained from VII by reacting with the corresponding aryl, heteroaryl or heterocyclyl sulfonyl chlorides as described above.
A preferred process for the preparation of a compound of formula I, wherein R1 to R7, A, E and G are defined as before comprises the reaction of a compound according to formula
Figure imgf000027_0001
in the presence of a compound according to formula
cr R
wherein R1 to R7, A, E and G are defined as before. Particularly preferred is the above process in the presence of a base such as trietylamine or (4- dimetylamino) -pyridine (DMAP) in a solvent such THF, ethanol, methylene chloride DMF or DMSO, or in pyridine as a solvent, with or without the addition of a base such as trietylamine or DMAP, at room temperature or at elevated temperatures.
Preferred intermediates are:
5- (2-chloro-phenyl) -pyridin-2-ylamine;
5- (2,4-dichloro-phenyl) -pyridin-2-ylamine;
5- (2-chloro-phenyl) -6-methyl-pyridin-2-ylamine; 5-(2-chloro-4-fluoro-phenyl)-pyridin-2-ylamine;
5- (3-fluoro-phenyl)- pyridin-2-ylamine;
5- (2,4-difluoro-phenyl) -pyridin-2-ylamine;
5-(4-methoxy-phenyl)-pyridin-2-ylamine; 5- (4-fluoro-phenyl) -pyridin-2-ylamine;
5- (2-methoxy-phenyl) -pyridin-2-ylamine;
5-(2-fluoro-phenyl)-pyridin-2-ylamine;
5- (2-chloro-phenyl) -pyridin-2-ylamine;
5- (4-methanesulfonyl-phenyl) -pyridin-2-ylamine; 5- (4-fluoro-phenyl) -6-methyl- pyridin-2-ylamine;
5-(3-fluoro-phenyl)-6-methyl-pyridin-2-ylamine;
5-(2,3-dichloro-phenyl)-pyridin-2-ylamine;
5-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamine;
5- (2,5-dichloro-phenyl) -pyridin-2-ylamine; 5-(2-fluoro-5-trifluoromethyl -phenyl) -pyridin-2-ylamine;
5-(2-trifluoromethyl -phenyl)-pyridin-2-ylamine;
5-(2,3-difluoro-phenyl)-pyridin-2-ylamine;
5-(2,4-bis-trifluoromethyl-phenyl)-pyridin-2-ylamine;
5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine; 5-(2,4-chloro-phenyl)-6-methyl-pyridin-2-ylamine;
5-(5-fluoro-2-methyl-phenyl)-pyridin-2-ylamine;
5-(5-chloro-2-methyl-phenyl)-pyridin-2-ylamine;
5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-ylamine;
5- ( 5-Chloro-2-methyl-phenyl) -6-methyl-pyridin-2-ylamine; 5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6-methyl-pyridin-2-ylamine;
5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine;
5-(5-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-ylamine;
5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine;
5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-ylamine; 5-(2-Fluoro-phenyl)-6-methyl-pyridin-2-ylamine;
5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2-ylamine;
2-Methyl-[3,3']bipyridinyl-6-ylamine;
5-(2-Chloro-phenyl)-4-methyl-pyridin-2-ylamine and
5- (4-Fluoro-2-methyl-phenyl) -4-methyl-pyridin-2-ylamine. The compounds of formula I described above for use as therapeutically active substance are a further object of the invention.
Also an object of the present invention are compounds as decribed above for the preparation of medicaments for the prophylaxis and therapy of illnesses which are caused by disorders associated with the enzyme 1 lbeta-hydroxysteroid dehydrogenasel (HbHSDl).
Likewise an object of the invention are pharmaceutical compositions comprising a compound of the formula I as described above and a therapeutically inert carrier.
A further preferred embodiment of the present invention is the use of a compound of the formula I as described above for the preparation of medicaments for the treatment and prophylaxis of diabetes, obesity, eating disorders, dyslipidemiae and hypertension.
Particularly preferred is the use of a compound according to formula I as described above for the preparation of medicaments for the treatment and prophylaxis of diabetes Type II.
A further object of the present invention comprises a compound according to formula I as described above, when manufactured according to any one of the described processes.
Also an object of the invention is a method for the treatment and prophylaxis of diabetes, obesity, eating disorders, dyslipidemiae and hypertension, which method comprises administering an effective amount of a compound of formula I as described above.
Particularly preferred is a method for the treatment and prophylaxis of diabetes Type II, which method comprises administering an effective amount of a compound according to formula I as described above.
Assay Procedures
Transient expression and partial Purification: The cDNA encoding the human llbeta-HSDl protein was cloned into the expression vector pcDNA3 (Stratagene). This construct (for details see Alex Odermatt et al.; J Biol Chem.,1999, Vol. 274, Issue 40, 28762-28770) was used to transiently express the protein in HEK293 cells (ATCC number: CRL-1573, described in Graham, F.L., Smiley, J., Russell, W.C., Nairn, R.; (1977)) using lipofectamine. 48h after transfection cells were washed twice with ice-cold PBS (Phsophate buffered Saline). To 1 volume of cell suspension in PBS 2 volumes of ice-cold lysis buffer (5OmM Tris; pH7.5; ImM EDTA; 10OmM NaCl) were added. The cells were lysed by Potter-homogenization (20 strokes). The resulting homogenate was sonicated wit a tip sonicator (10% output; 2 x 30 sec.) and cleared by a low speed centrifugation (lOmin x 900Og; 4°C). The microsomal fraction was collected by a high speed centrifugation (60 min x 110'OOOg). The resulting pellet was resuspended in storage buffer (2OmM Tris pH 7.5; 1 mM EDTA; 10% Glycerol) and the centrifugation was repeated. The resulting pellet containing the microsomal fraction was again taken up into storage buffer and aliquots were kept frozen in liquid Nitrogen until use.
Generation of stable cell lines expressing llbeta-HSDl:
The same construct used for transient expression of human llbeta-HSDl was also used to establish cell lines stably expressing the protein. Briefly, (HEK293) cells were transfected with llbeta-HSDl construct using the lipofectamine reagent (Gibco BRL) according to the manufacturer's instruction. Two days after transfection, geneticin selection (0.8 mg/ml) was initiated and several stable clones were isolated. One clone was further used for pharmacological characterization.
Microsome Assay
Microsomes isolated from HEK293 cells transiently expressing human llbeta-HSDl (for details see above) were incubated in assay buffer (100 mM NaCl; ImM EDTA; ImM EGTA; ImM MgCl; 250 mM Sucrose; 20 mM Tris pH 7.4; Cortisone 50-20OnM and NADPH ImM) together with different concentrations of test substances. After 60 min. of incubation at 370C the assay was stopped by heating to 800C (5 min.) and by addition of the inhibitor Carbenoxolone (1 uM). The amount of Cortisol produced in this assay was determined using a commercially available, ELISA-based Cortisol-detection kit (Distributed by Assay Design, Inc.). Inhibitors were characterized by there IC50 values, e.g. the concentration at which the production of Cortisol was 50% reduced.
In this test preferred compounds as described above have IC50 values below 1000 nM; more preferred compounds have IC50 values below 100 nM. Most preferred compounds have IC50 values below 1OnM.
Cellular Assay
To measure the effect of inhibitors in intact cells HEK293 cells stably expressing human llbeta-HSDl (see above) were cultivated in 96 well plates in DMEM. First inhibitors and 60 min later Cortisone was added to the cells. After 60 min of incubation at 37°C in a 5% CO2 atmosphere part of the medium was removed and the conversion from Cortisone to Cortisol was measured using a commercially available ELISA kit (Distributed by Assay Design, Inc.).
Results obtained in the microsome assay using representative compounds of the invention as the test compounds are shown in the following table:
Figure imgf000031_0001
Compounds as described above have ICs0 values below 1000 nM; preferred compounds have IC50 values below 100 nM. More preferred compounds have IC50 values below 10 nM. These results have been obtained by using the foregoing test. The compounds of formula I and their pharmaceutically acceptable salts and esters can be used as medicaments (e.g. in the form of pharmaceutical preparations). The pharmaceutical preparations can be administered internally, such as orally (e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatin capsules, solutions, emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in the form of suppositories). However, the administration can also be effected parentally, such as intramuscularly or intravenously (e.g. in the form of injection solutions).
The compounds of formula I and their pharmaceutically acceptable salts and esters can be processed with pharmaceutically inert, inorganic or organic adjuvants for the production of tablets, coated tablets, dragees and hard gelatin capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragees and hard gelatin capsules.
Suitable adjuvants for soft gelatin capsules, are, for example, vegetable oils, waxes, fats, semi-solid substances and liquid polyols, etc.
Suitable adjuvants for the production of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose, etc.
Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc.
Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semi-solid or liquid polyols, etc.
Moreover, the pharmaceutical preparations can contain preservatives, solubilizers, viscosity-increasing substances, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
In accordance with the invention the compounds of formula I and their pharmaceutically acceptable salts can be used for the prophylaxis and treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity. The dosage can vary in wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 0.1 mg to 20 mg per kg body weight, preferably about 0.5 mg to 4 mg per kg body weight (e.g. about 300 mg per person), divided into preferably 1-3 individual doses, which can consist, for example, of the same amounts, should be appropriate. It will, however, be clear that the upper limit given above can be exceeded when this is shown to be indicated.
The invention is illustrated hereinafter by Examples, which have no limiting character.
Examples
Example 1 a) A solution of 0.2 g (0.98 mmol) of 5-(2-chloro-phenyl)-pyridin-2-ylamine and 0.23 g of 5-fiuoro-2-methyl-benzenesulfonyl chloride (1.1 mmol) in pyridine (10 ml) was stirred at RT until completion of reaction according to HPLC analysis (48 h). After concentration in vacuo the residue was taken up in EtOAc, the solution washed withl N aqueous HCl, saturated brine then dried over sodium sulphate and concentrated in vacuo. The precipitate was collected by filtration and dried in a high vacuum to give 0.21 g (57%) of N-[5-(2-chloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide as an off- white crystalline solid. ISN mass spectrum, m/e: 375.2 (M-I calculated for C18H14ClFN2O2S: 375).
Preparation of the starting material:
b) A suspension of 70 mg (0.06 mmol) of tetrakis(triphenylphosphine) palladium(O) in benzene (4 ml) was treated at RT under an argon atmosphere successively with 0.35 g (2 mmol) of 2-amino-5-bromo-pyridine, 2.2 ml (4.4 mmol) of 2 M aqueous Na2CO3 solution, 0.34 g (2.2 mmol) of 2-chlorophenylboronic acid in ethanol (1 ml) and heated to reflux for 24 h. The reaction mixture was cooled and partitioned between EtOAc and water. The layers were separated, the organic layer dried over sodium sulphate and concentrated in vacuo. The residue was applied to a silica gel column with EtOAc as eluent. Combination of the purified fractions and concentration in vacuo gave 0.4 g (98%) of the desired 5-(2-chloro-phenyl)-pyridin-2-ylamine as white crystalline solid. ISP mass spectrum, m/e: 205.1 (M+ 1 calculated for C11H9ClN2: 205).
Example 2
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 3- chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-chloro-N-[5-(2-chloro- phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 391 (M-I calculated for C18H14Cl2N2O2S: 391).
Example 3 a) In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-dichloro- phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 409 (M-I calculated for Ci8 H13Cl2FN2O2 S: 409).
Preparation of the starting material:
b) In analogy to example Ib), on reaction of 2-amino-5-bromo-pyridine with 2,4- dichlorophenylboronic acid there was obtained: 5-(2,4-dichloro-phenyl)-pyridin-2- ylamine as a white crystalline solid which was used without further purification in the subsequent reaction step.
Example 4a
In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 3- chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,4- dichloro-phenyl)-pyridin-2-yl] -2-methyl-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 425 (M-I calculated for C18Hi3Cl3N2O2S: 425).
Example 4b a) In analogy to example 1, on reaction of 5-(2-cMoro-phenyl)-6-methyl-pyridin-2- ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro- N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 405.1 (M-I calculated for C19 H16Cl2N2O2S: 405).
Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-bromo-6-methyl-pyridin-2-ylamine with 2- chlorophenylboronic acid there was obtained: 5-(2-chloro-phenyl)-6-methyl-pyridin-2- ylamine as a white crystalline solid. ISP mass spectrum, m/e: 219.2 (M+ 1 calculated for C12 H11ClN2: 219).
Example 5
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with biphenyl-4-sulfonyl chloride there was obtained: Biphenyl-4-sulfonic acid [5-(2- chloro-phenyl)-6-methyl-pyridin-2-yl] -amide as a white foam. ISN mass spectrum, m/e: 433.2 (M-I calculated for C24H19ClN2O2S: 433).
Example 6 a) In analogy to example 1, on reaction of 5-(2-chloro-4-fluoro-phenyl)-pyridin-2- ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro- N-[5-(2-chloro-4-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as an amorphous white solid. ISN mass spectrum, m/e: 409 (M-I calculated for Qs H13 Cl2FN2O2S: 409).
Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-bromo-pyridin-2-ylamine with 2-chloro-4- fluoro-phenylboronic acid there was obtained: 5-(2-chloro-4-fluoro-phenyl)- pyridin-2- ylamine as a white crystalline solid which was used without further purification in the next reaction step. Example 7 a) In analogy to example 1, on reaction of 5-(3-fluoro-phenyl)- pyridin-2-ylamine with 3- chloro-2-rnethyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(3-fluoro- phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 375.2 (M-I calculated for C18Hi4ClFN2O2S: 375).
Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-bromo-pyridin-2-ylamine with 3-fluro- phenylboronic acid there was obtained: 5-(3-fluoro-phenyl)- pyridin-2-ylamine as a white crystalline solid which was used without further purification in the next reaction step.
Example 8 a) In analogy to example 1, on reaction of 5- (2,4-difluoro-phenyl) -pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,4- difluoro-phenyl)-pyridin-2-yl] -2-methyl-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 392.9 (M-I calculated for C18Hi3ClF2N2O2S: 392).
Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-bromo-pyridin-2-ylamine with 2,4- difluoro-phenylboronic acid there was obtained: 5-(2,4-difiuoro-phenyl)-pyridin-2- ylamine as a white crystalline which was used without further purification in the next reaction step.
Example 9 In analogy to example 1, on reaction of 5- (2,4-difluoro-phenyl) -pyridin-2-ylamine with 5- fluoro-2-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Difluoro- phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 377.1 (M-I calculated for Ci8Hi3F3N2O2S: 377). Example 10 a) In analogy to example 1, on reaction of 5-(4-methoxy-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4- methoxy-phenyl)-pyridin-2-yl]-2-memyl-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 387.1 (M-I calculated for C19H17ClN2O2S: 387).
Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-bromo-pyridin-2-ylamine with 4-methoxy- phenylboronic acid there was obtained: 5-(4-methoxy-phenyl)-pyridin-2-ylamine as a beige crystalline solid which was used without further purification in the next reaction step.
Example 11 a) In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-pyridin-2-ylamine with 3- chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N- [5-(4-fluoro- phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 375.2 (M-I calculated for C18H14ClFN2O2S: 375).
Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-brorno-pyridin-2-ylamine with 4-fiuoro- phenylboronic acid there was obtained: 5-(4-fluoro-phenyl)-pyridin-2-ylamine as a brown crystalline solid which was used without further purification in the next reaction step.
Example 12 In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-pyridin-2-ylamine with 5- fluoro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4-fluoro- phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a crystalline off-white solid. ISN mass spectrum, m/e: 359 (M-I calculated for C18H14F2N2O2S: 359).
Example 13 a) In analogy to example 1, on reaction of 5-(2-methoxy-phenyl)-pyridin-2-ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: 5-Fluoro-N-[5-(2- methoxy-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 371.1 (M-I calculated for C19H17FN2O3S: 371).
Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-bromo-pyridin-2-ylamine with 2-methoxy- phenylboronic acid there was obtained: 5-(2-methoxy-phenyl)-pyridin-2-ylamine as yellow oil which was used without further purification in the next reaction step.
Example 14 a) In analogy to example 1, on reaction of 5-(2-fluoro-phenyl)-pyridin-2-ylamine with 3- chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-fluoro- phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 375.2 (M- 1 calculated for C18H14ClFN2O2S: 375) .
Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-bromo-pyridin-2-ylamine with 2-fluoro- phenylboronic acid there was obtained: 5-(2-fluoro-phenyl)-pyridin-2-ylamine as yellow oil which was used without further purification in the next reaction step.
Example 15
In analogy to example 1, on reaction of 5-(2-fluoro-phenyl)-pyridin-2~ylamine with 5- fluoro-2-methyl-benzenesulfonyl chloride there was obtained: 5-Fluoro-N-[5-(2-fluoro- phenyl) -pyridin -2 -yl]-2-methyl-benzenesulfonamide as amorphous white solid. ISN mass spectrum, m/e: 359 (M-I calculated for C18H14F2N2O2S: 359).
Example 16 In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 2,4- dichloro-6-methyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5-(2- chloro-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide as a colourless crystalline solid. ISP mass spectrum, m/e: 425 (M-I calculated for C18H13Cl3N2O2S: 425).
Example 17
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 2,5- difluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-chloro-phenyl)-pyridin-2- yl]-2,5-difluoro-benzenesulfonamide as a white crystalline solid. ISN mass spectrum, m/e: 379 (M-I calculated for C17H11ClF2N2O2S: 379).
Example 18 a) In analogy to example 1, on reaction of 5-(4-methanesulfonyl-phenyl)-pyridin-2- ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro- N-[5-(4-methanesulfonyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as an amorphous white solid. ISN mass spectrum, m/e: 435.1 (M-I calculated for
Figure imgf000039_0001
Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-bromo-pyridin-2-ylamine with 4- methanesulfonyl-phenylboronic acid there was obtained: 5-(4-methanesulfonyl-phenyl)- pyridin-2-ylamine as a white crystalline solid which was used without further purification in the next reaction step.
Example 19 a) In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2- ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro- N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide as a yellow foam. ISN mass spectrum, m/e: 389 (M-I calculated for Ci9Hi6ClFN2O2S: 389). Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-bromo-6-methyl-pyridin-2-ylamine with 4- fluoro-phenylboronic acid there was obtained: 5-(4-mioro-ρhenyl)-6-methyl-pyridin-2- ylamine as a yellow crystalline solid which was used without further purification in the next reaction step.
Example 20
In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: 5-Fluoro-N-[5-(4- fluoro-phenyl)-6-methyl-pyridin-2-yl] -2-methyl-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 373.1 (M-I calculated for C19H16F2N2O2S: 373).
Example 21 a) In analogy to example 1, on reaction of 5-(3-fluoro-phenyl)-6-methyl-pyridin-2- ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro- N-[5-(3-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide as a yellow foam. ISN mass spectrum, m/e: 389.1(M-I calculated for C19H16ClFN2O2S: 389).
Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-bromo-6-methyl-pyridin-2-ylamine with 3- fluoro-phenylboronic acid there was obtained: 5-(3-fluoro-phenyl)-6-methyl-pyridin-2- ylamine as a white crystalline solid which was used without further purification in the next reaction step.
Example 22
In analogy to example 1, on reaction of 5-(3-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: 5-Fluoro-N-[5-(3- fluoro-phenyl)-6-methyl-pyridin-2-yl] -2-methyl-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 373.1(M-I calculated for C19H16F2N2O2S: 373). Example 23
In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 3,4-dimethyoxy-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro- phenyl)-pyridin-2-yl]-3,4-dimethoxy-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 437.1(M-I calculated for C19H16Cl2N2O4S: 437).
Example 24
In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 3,4-dichloro-benzenesulfonyl chloride there was obtained: 3,4-Dichloro-N-[5-(2,4- dichloro-phenyl)-pyridin-2-yl]-benzenesulfonamide as an crystalline white solid. ISN mass spectrum, m/e: 446.9 (M-I calculated for C17H10Cl4N2O2S: 447).
Example 25 a) In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with 2,5-difluoro-benzenesulfonyl chloride there was obtained: N- [5- (2,3-dichloro-phenyl) - pyridin-2-yl] -2,5-difluoro-benzenesulfonamide as a light- red solid. ISN mass spectrum, m/e: 413 (M-I calculated for C17H10Cl2F2N2O2S: 413).
Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-bromo -pyridin-2-ylamine with 2,3- dichloro-phenylboronic acid there was obtained: 5-(2,3-dichloro-phenyl)-pyridin-2- ylamine as an of- white crystalline solid. EI mass spectrum, m/e: 239.1 (M calculated for CnH8Cl2N2: 239).
Example 26
In analogy to example 1, on reaction of 5-(2)3-dichloro-phenyl)-pyridin-2-ylamine with 3- chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,3- dichloro-phenyl) -pyridin-2-yl] -2-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 427 (M-I calculated for Ci8H13Cl3N2O2S: 427). Example 27
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 3,4- dichloro-benzenesulfonyl chloride there was obtained: 3,4-dichloro-N-[5-(2-chloro- phenyl) -pyridin-2-yl] -benzenesulfonamide as a white crystalline solid. ISN mass spectrum, m/e: 411 (M-I calculated for C17H11Cl3N2O2S: 411).
Example 28
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 3,4dimethoxy-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)- pyridin-2-yl] -3,4-dimethoxy-benzenesulfonamide as a white crystalline solid. ISN mass spectrum, m/e: 403.2 (M-I calculated for C19H17ClN2O4S: 403).
Example 29
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 3- chloro-4-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-chloro- phenyl) -pyridin-2-yl] -4-methyl-benzenesulfonamide as a white crystalline solid. ISN mass spectrum, m/e: 391 (M+ 1 calculated for C18H14Cl2N2O4S: 391).
Example 30 a) In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2- ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: 5-Fluoro- N- [5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a light- yellow solid. ISN mass spectrum, m/e: 373 (M-I calculated for Ci9H16F2N2O2S: 373).
Preparation of the starting material: b) In analogy to example Ib), on reaction of 5-bromo -pyridin-2-ylamine with 4-fluoro-2- methyl-phenylboronic acid there was obtained: 5-(4-fluoro-2-methyl-phenyl)-pyridin-2- ylamine as a white solid. ISP mass spectrum, m/e: 203.1 (M+l calculated for C12HnFN2: 203).
Example 31 In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4- fluoro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a light-yellow solid. ISN mass spectrum, m/e: 389.1(M-I calculated for C19H16ClFN2O2S: 389).
Example 32
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 3- chloro-4-methoxy-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2- chloro-phenyl)-pyridin-2-yl]-4-methoxy-benzenesulfonamide as a white solid. ISP mass spectrum, m/e: 409.2 (M+l calculated for C18H14Cl2N2O3S: 409).
Example 33
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 4,5- dichloro-2-fluoro-benzenesulfonyl chloride there was obtained: 4,5-Dichloro-N-[5-(2- cHoro-phenyl)-pyridin-2-yl]-2-fluoro-benzenesulfonamide as a white solid. ISP mass spectrum, m/e: 431.2 (M+l calculated for C17H10Cl3FN2O3S: 431).
Example 34
In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 3- chloro-4-methoxy-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,4- dichloro-phenyl) -pyridin-2-yl] -4-methoxy-benzenesulfonamide as an crystalline white solid. ISP mass spectrum, m/e: 443.1(M+1 calculated for C18H13Cl3N2O3S: 443).
Example 35 In analogy to example 1, on reaction of 5-(2,4-dicHoro-phenyl)-pyridin-2-ylamine with 3- chloro-4-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5~(2,4- dicMoro-phenyl) -pyridin-2-yl] -4-methyl-benzenesulfonamide as an crystalline white solid. ISP mass spectrum, m/e: 427.2 (M+ 1 calculated for Ci8H13Cl3N2O2S: 427).
Example 36
A solution of 0.23 g (1 mmol) of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine and 0.2 g (1.1 mmol) of piperidine-1-sulfonyl chloride (preparation: BuU.Soc.Chim.Fr.; 1936, p2143) in pyridine (10 ml) was heated to reflux until completion of reaction according to HPLC analysis (20 h). After concentration in vacuo the residue was taken up in EtOAc, which was then washed with IN aqueous HCl, saturated brine, dried over sodium sulphate and concentrated in vacuo. The residue was applied to a silica gel column with EtO Ac/toluene (9/1 to 1/1) as eluent. Combination of the purified fractions and concentration in vacuo gave 0.26 g (67%) of the desired piperidine-1 -sulfonic acid [5-(2,4-dichloro-phenyl)- pyridin-2-yl] -amide as a brown crystalline solid. ISN mass spectrum, m/e: 384 (M-I calculated for C16Hi7Cl2N2O2S: 384).
Example 37
In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with 2- txifluoromethyl-benzenesulfonyl chloride there was obtained: N- [5-(2,3-Dichloro- phenyl) -pyridin-2-yl] -2-trifluoromethyl-benzenesulfonamide as alight-red solid. ISN mass spectrum, m/e: 445 (M-I calculated for Ci8HnCl2FaN2O2S: 445).
Example 38
In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with 4- fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro-phenyl)-pyridin- 2-yl]-4-fluoro-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 395 (M-I calculated for Ci7HnCl2FN2O2S: 395). Example 39 a) In analogy to example 1, on reaction of 5- (2,5-dicHoro-phenyl) -pyridin-2-ylamine with 2,5-difluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,5-Dichloro-phenyl)- pyridm-2-yl]-2,5-difluoro-benzenesulfonamide as a light yellow amorphous solid. ISN mass spectrum, m/e: 413 (M-I calculated for C17H10Cl2F2N2O2S: 413).
Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-bromo -pyridin-2-ylamine with 2,3- dichloro-phenylboronic acid there was obtained: 5-(2,5-dichloro-phenyl)-pyridin-2- ylamine as an of- white crystalline solid. EI mass spectrum, m/e: 239.1 (M calculated for C11H8CL2N2: 239).
Example 40
In analogy to example 1, on reaction of 5- (2,5-dichloro-phenyl) -pyridin-2-ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,5-Dichloro- phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 409 (M-I calculated for C18H13Cl2FN2O2S: 409).
Example 41 In analogy to example 1, on reaction of 5-(2,5-dichloro-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,5- dichloro-ρhenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 427.1 (M-I calculated for C18H13Cl3N2O2S: 427).
Example 42 a) In analogy to example 1, on reaction of 5-(2-fluoro-5-trifluoromethyl -phenyl) -pyridin- 2-ylamine with 5-πuoro-2-methyl-benzenesulfonyl chloride there was obtained: 5-Fluoro- N-[5-(2-fluoro-5-trifluoromethyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid solid. ISN mass spectrum, m/e:427.2 (M-I calculated for QgH13F5N2O2S: 427). Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-bromo -pyτidin-2-ylamine with 2-fluoro-5- trifluoromethyl-phenylboronic acid there was obtained: 5-(2-fluoro-5-trmuoromethyl - phenyl) -pyridin-2-ylamine as a white solid. ISP mass spectrum, m/e: 257 (M+H calculated for C12H8F4N2: 257).
Example 43
In analogy to example 1, on reaction of 5-(2-fluoro-5-trifluoromethyl -phenyl) -pyridin- 2- ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro- N- [5-(2-fluoro-5-trifluoromethyl-phenyl)-pyridin-2-yl] -2-methyl-benzenesulfonamide as a white solid ISN mass spectrum, m/e: 442.9 (M-I calculated for C19H13ClF4N2O2S: 443).
Example 44 a) In analogy to example 1, on reaction of 5-(2-trifluoromethyl -phenyl) -pyridin-2- ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-2- methyl-N-[5-(2-trifluoromethyl-phenyl)-pyridin-2-yl]-benzenesulfonamide as an orange solid. ISN mass spectrum, m/e: 425 (M-I calculated for Ci9H14ClF3N2O2S: 425).
Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-bromo -pyridin-2-ylamine with 2- trifluoromethyl-phenylboronic acid there was obtained: 5-(2-trifluoromethyl-phenyl)- pyridin-2-ylamine as a white solid. ISP mass spectrum, m/e: 239.2 (M+H calculated for C12H9F3N2: 239).
Example 45
In analogy to example 1, on reaction of 5-(2-trifluoromethyl -phenyl) -pyridin-2-ylamine with 3-chloro-4-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-4-methyl- N-[5-(2-trifluoromethyl-phenyl)-pyridin-2-yl]-benzenesulfonamide as a light-grey solid solid. ISP mass spectrum, m/e: 425 (M-I calculated for C19Hi4ClF3N2O2S: 425). Example 46
In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 5- chloro-2-methoxy-benzenesulfonyl chloride there was obtained: 5-chloro-N-[5-(2,4- dichloro-phenyl) -pyridin-2-yl] -2-methoxy-benzenesulfonamide as a crystalline white solid. ISP mass spectrum, m/e: 443.1 (M+ 1 calculated for C18H13Cl3N2O3S: 443).
Example 47
In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 4- acetylamino-3-chloro-benzenesulfonyl chloride there was obtained: N-{2-Chloro-4- [5- (2,4-dichloro-phenyl)-pyridin-2-ylsulfamoyl]-phenyl}-acetamide as a crystalline brown solid. ISN mass spectrum, m/e: 468 (M-I calculated for C^HuCl3N3O3S: 468).
Example 48 In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 4- trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro- phenyl) -pyridin-2-yl] -4-trifluoromethyl-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 445 (M-I calculated for C18H11Cl2F3N2O2S: 445)
Example 49
In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 4- methylsulfonyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro-phenyl)- pyridin-2-yl]-4-methysulfonyl-benzenesulfonamide as a crystalline light-brown solid. ISN mass spectrum, m/e: 455.1 (M-I calculated for C18Hi4Cl2N2O4S2: 455).
Example 50 a) In analogy to example 1, on reaction of 5-(2,3-difluoro-phenyl)-pyridin-2-ylarnine with 3-chloro-4-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,3- difluoro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 392.9 (M-I calculated for Ci8Hi3ClF2N2O2S: 393).
Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-bromo -pyridin-2-ylamine with 2,3- difluoro-phenylboronic acid there was obtained: 5-(2,3-difluoromethyl-phenyl)-pyridin- 2-ylamine as a white solid. ISP mass spectrum, m/e: 207.2 (M+H calculated for CnH8F2N2: 207).
Example 51
In analogy to example 1, on reaction of 5-(2,3-difluoro-phenyl)-pyridin-2-ylamme with 3- fluoro-2-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Difluoro- phenyl)-pyridin-2-yl]-5-fluoro-2-meώyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: x377.2 (M-I calculated for C18H13F3N2O2S: 377).
Example 52 a) In analogy to example 1, on reaction of 5-(2,4-bis-trifluoromethyl-phenyl)-pyridin-2- ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: N- [5- (2,4- Bis-trifluoromethyl-phenyl)-pyridin-2-yl] -3-chloro-2-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 493 (M-I calculated for C20Hi3ClF6N2O2S: 493).
Preparation of the starting material:
b) In analogy to example Ib), on reaction of 5-bromo -pyridin-2-ylamine with 2,4-bis- trifluoromethyl-phenylboronic acid there was obtained: 5-(2,4-bis-trifluoromethyl- phenyl) -pyridin-2-ylamine as a white solid. ISP mass spectrum, m/e: 307.2 (M+ 1 calculated for C13H8F6N2: 307).
Example 53 a) In analogy to example 1, on reaction of 5- (2,4-bis-trifluoromethyl- phenyl) -pyridin-2- ylamine with 3-cMoro-4-methyl-benzenesulfbnyl chloride there was obtained: N-[5-(2,4- Bis-trinuoromethyl-phenyl)-pyridin-2-yl] -3-chloro-4-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 493 (M-I calculated for C20H13ClF6N2O2S: 493).
Example 54
In analogy to example 1, on reaction of 5-(2,3-difluoro-phenyl)-pyridin-2-ylamine with 3- chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,3- difluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 392 (M-I calculated for C18H13ClF2N2O2S: 392).
Example 55
In analogy to example XX, on reaction of 5-(2,3-dichloro-phenyl)- pyridin-2-ylamine with piperidine-1-sulfonyl chloride there was obtained: Piperidine-1- sulfonic acid [5-(2,3- dichloro-phenyl)-pyridin-2-ylj -amide as an off-white solid. ISN mass spectrum, m/e: 384(M-I calculated for C16H17Cl2N3O2S: 384).
Example 56
In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl~pyridin-2-ylamine with 5-chloro-2-methoxy-benzenesulfonyl chloride there was obtained: 5-Chloro-N- [5-(4- fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methoxy-benzenesulfonamide as a crytalline white solid. ISN mass spectrum, m/e: 405.2 (M-I calculated for C19H16ClFN2O3S: 405).
Example 57 In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 4-acetylamino3-chloro-benzenesulfonyl chloride there was obtained: N-{2-Chloro-4- [5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylsulfamoyl] -phenyl}-acetamide as a light- brown solid. ISN mass spectrum, m/e: 432.2 (M-I calculated for C20Hi7ClFN3O3S: 432). Example 58
In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 4-trinuormethyl-benzenesulfonyl chloride there was obtained: N-[5-(4-Fluoro- phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide as a brown foam. ISN mass spectrum, m/e: 409 (M- 1 calculated for C19H14F4N2O2S: 409) .
Example 59
In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 4-methanesulfonyl-benzenesulfonyl chloride there was obtained: N-[5-(4-Fluoro- phenyl)-6-methyl-pyridin-2-yl]-4-methanesulfonyl-benzenesulfonarnide as a brown viscous oil. ISN mass spectrum, m/e: 419 (M-I calculated for C19H17FN2O4S2: 419).
Example 60
In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with (4-chlorosulfonyl-phenoxy)-acetic acid methyl ester there was obtained: {4- [5-(2,3- dichloro-phenyl)-pyridin-2-ylsulfamoyl]-phenoxy}-acetic acid methyl ester as a white solid. ISN mass spectrum, m/e: 465 (M-I calculated for C20H16Cl2N2OsS: 465).
Example 61
In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 4-tτifluorornethoxy-benzenesulfonyl chloride there was obtained: N- [5- (4- Fluorophenyl)-6-methyl-pyridin-2-yl] -4-trinuoromethoxy-benzenesulfonamide as a light- brown foam. ISP mass spectrum, m/e: 427.3 (M+ 1 calculated for C19H14F4N2O3S: 427).
Example 62
In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-4-methoxy-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4- fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-methoxy-benzenesulfonamide as a light-brown foam. ISN mass spectrum, m/e: 405.1 (M-I calculated for C19H16ClFN2O3S: 405). Example 63
In analogy to example 1, on reaction of 5-(4-fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 4-chloro-2,5-dimethyl-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5- (4-fluoro-phenyl)-6-methyl-pyridin-2-yl] -2,5-dimethyl-benzenesulfonamide as a light- brownfoam. ISN mass spectrum, m/e: 403.1 (M-I calculated for C20H18ClFN2O2S: 403).
Example 64
A solution of 120 mg (2.6 mmol) of 4-[5-(2,3-DicHoro-ρhenyl)-pyridin-2-ylsulfamoyl]- phenoxyj-acetic acid methyl ester, product of example 60, in THF/EtOH (each 5 ml) was treated with 57 mg (5.1 mmol) of CaCl2, cooled to 0° C and then 39 mg (1 mmol) of sodium borohydride were added portionwise. The mixture was stirred for 12 h at RT, poured into ice/water acidified with 3 M HCl to pH 1 and extracted with AcOEt._The layers were separated, the organic layer dried over sodium sulphate and concentrated in vacuo. The residue was applied to a silica gel column with EtOAc/heptan (1/1) then
CH2Cl2/MeOH (95/5) as eluent. Combination of the purified fractions and concentration in vacuo gave 0.1 g (93%) of the desired N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-(2- hydroxy-ethoxy)-benzenesulfonamide as white foam. ISN mass spectrum, m/e: 437.2 (M-I calculated for Ci9Hi6Cl2N2O4S: 437).
Example 65
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-6- methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 375.2 (M-I calculated for Ci8Hi4ClFN2O2S: 375).
Example 66
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-4-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2- chloro-phenyl)-6-methyl-pyridin-2-yl]-4-methyl-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 405.2 (M-I calculated for C19H16Cl2N2O2S: 405).
Example 67
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-chloro-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5-(2-chloro- phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 391 (M-I calculated for C18H14Cl2N2O2S: 391).
Example 68
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4,6-dichloro-2-methyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N- [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 439 (M-I calculated for C19H15Cl3N2O2S: 439).
Example 69
In analogy to example 36, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4 piperidine-1-sulfonyl chloride there was obtained: Piperidine-1 -sulfonic acid [5-(2- chloro-phenyl)-6-methyl-pyridin-2-yl] -amide as a white foam. ISN mass spectrum, m/e: 364 (M- 1 calculated for C17H20ClN3O2S: 364) .
Example 70
In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 4- fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro-phenyl)-pyridin- 2-yl] -4-fluoro-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 394.9 (M-I calculated for Ci7HnCl2FN2O2S: 395).
Example 71 In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 4- chloro-2,5-dimethyl-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5-(2,4- dichloro-ρhenyl)-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide as an amorphous white solid. ISN mass spectrum, m/e: 439 (M-I calculated for C19H15Cl3N2O2S: 439).
Example 72
In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 2,4-difiuoro-benzenesulfonyl chloride there was obtained: N-[5-(2,4-dichloro-phenyl)- pyridin-2-yl]-2,4-difluoro-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 413.1 (M-I calculated for C17H10Cl2F2N2O2S: 413).
Example 73
In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 2,4-dichloro-5-methyl-benzenesulfonyl chloride there was obtained: 2,4-EKchloro-N-[5- (2,4-dichloro-phenyl) -pyridin-2-yl] -5-methyl-benzenesulfonamide as a amorphous white solid. ISN mass spectrum, m/e: 459 (M-I calculated for C18H12Cl4F2N2O2S: 459).
Example 74
In analogy to example 1, on reaction of 5-(2J3-dichloro-phenyl)-pyridin-2-ylamine with 3- trifluoromeώyl-benzenesulfonyl chloride there was obtained: N- [5-(2,3-Dichloro- phenyl) -pyridin-2-yl] -3-trifluoromethyl-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 445 (M-I calculated for C1SH11Cl2FaNaO2S: 445).
Example 75 a) In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl- pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: 4-Fluoro- N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 373.1 (M-I calculated for C19H16F2N2O2S: 373). 94
- 53 -
Preparation of the starting material: b) In analogy to example Ib), on reaction of 5-bromo -6-methyl-pyridin-2-ylamine with 4-fluoro-2-methyl-phenylboronic acid there was obtained: 5-(4-Fluoro-2-methyl-phenyl)- 6-methyl-pyridm-2-ylamine as a yellow solidwhich was used directly in the next reaction step.
Example 16
In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin- 2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro- N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 403.2 (M-I calculated for C2oHiaClFN202S: 403).
Example 11
In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin- 2-ylamine with 5-fluoro-2-methyl-benzenesulfonyl chloride there was obtained: 5-Fluoro- N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 387.1 (M-I calculated for C20H18F2N2O2S: 387).
Example 78
In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with 3- chloro-4-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,3- dichloro-phenyl)-pyridin-2-yl] -4-methyl-benzenesulfonamide as awhite solid. ISN mass spectrum, m/e: 425 (M-I calculated for C18H13Cl3N2O2S: 425).
Example 79 In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyτidin-2-ylamine with 4- trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro- phenyl)-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 444.9 (M-I calculated for Ci8Hi1Cl2F3N2O2S: 445).
Example 80 a) In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2- ylamine with 3-chloro-4-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro- N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-methyi-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 389 (M-I calculated for Ci9Hi6ClFN2O2S: 389).
Example 81 a) In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2- ylamine with 3-trifluoromeUiyl-benzenesulfonyl chloride there was obtained: N- [5- (4- Fluoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifiuoromethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 409 (M-I calculated for C19Hi4F4N2O2S: 409).
Example 82 a) In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2- ylamine with 4-trifluoromethyl-benzenesulfonyl chloride there was obtained: N- [5- (4- Fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 409 (M-I calculated for C19H14F4N2O2S: 409).
Example 83 In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 3- trifluromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)- pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 411 (M-I calculated for Ci8Hi2ClF3N2O3S: 411). Example 84
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 4- ethyl-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-pyridin-2-yl]- 4-ethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 371.1 (M-I calculated for Ci9H17ClN2O2S: 371).
Example 85
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 3- chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-chloro-phenyl)- pyridin-2-yl]-benzenesulfonamide as white crystals. ISN mass spectrum, m/e: 377.1 (M-I calculated for C17H12Cl2N2O3S: 377).
Example 86
In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 3- chloro-4-fluoro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,4- dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 429.1 (M-I calculated for C17H10Cl3FN2O2S: 429).
Example 87 In analogy to example 1, on reaction of 5-(2,4-dichloro-ρhenyl)-pyridin-2-ylamine with 4- ethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro-phenyl)-pyridin- 2-yl]-4-ethyl-benzenesulfonamide as a crystalline white solid. ISN mass spectrum, m/e: 405.1 (M-I calculated for C19H16Cl2N2O2S: 405).
Example 88 a) In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro- phenyl)-pyridin-2-yl]-3-trifluoromemyl-benzenesulfonamide as an white foam. ISP mass spectrum, m/e: 444.9 (M-I calculated for C18 HnCl2F3N2O2 S: 445).
Example 89
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro- phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 425 (M-I calculated for C19 H14ClF3N2O2S: 425).
Example 90
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-trifluoromethoxy-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro- phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethoxy-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 441.1 (M-I calculated for C19 Hi4ClF3N2O3S: 441).
Example 91
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)~pyridin-2-ylamine with 4- fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-pyridin-2- yl]-4-fluoro-benzenesulfonarnide as a white solid. ISN mass spectrum, m/e: 361 (M-I calculated for C17H12ClFN2O2S: 361).
Example 92
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-pyridin-2-ylamine with 2,4- difluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-pyridin-2- yl]-2,4-difluoro-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 379 (M-I calculated for Ci7H11ClF2N2O2S: 379).
Example 93 In analogy to example 1, on reaction of 5-(2-cHoro-phenyl)-pyridin-2-ylamine with 4- chloro-2,5-dimethyl-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5-(2- chloro-phenyl)-pyridin-2-yl]-2,5-dimethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 405.1 (M-I calculated for C19H16Cl2N2O2S: 405).
Example 94
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-chloro-2,5-dimethyl-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5- (2-chloro-phenyl)-6-methyl-pyridin-2-yl]-2,5-dimethyl- benzenesulfonamide as an off- white solid. ISN mass spectrum, m/e: 419 (M-I calculated for C20 H18Cl2N2O2S: 419).
Example 95
In analogy to example 1, on reaction of 5-(2-cMoro-phenyl)-6-methyl-pyridin-2-ylamine with 2,4-difluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)- 6-methyl-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 392.9 (M+l calculated for Ci8 H13ClF2N2O2S: 393).
Example 96
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3,5-dichloro-benzenesulfonyl chloride there was obtained: 3,5-Dichloro-N- [5-(2- chloro-phenyl)-6-methyl-pyridin-2-yl] -benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 425 (M-I calculated for Ci8 H13Cl3N2O2S: 425).
Example 97 a) In analogy to example 1, on reaction of 5-(2,4-chloro-phenyl)-6-methyl-pyridin-2- ylamine with 3-trifiuoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4- Dichloro-phenyl)-6-methyl-pyridin-2-yl] -3-trifluoromethyl-benzenesulfonamide as an colourless waxy solid. ISN mass spectrum, m/e: 459 (M-I calculated for Qg
Figure imgf000058_0001
Preparation of the starting material: b) In analogy to example Ib), on reaction of 5-bromo -6-methyl-pyridin-2-ylamine with 2,4-dichloro-phenylboronic acid there was obtained: of 5-(2,4-chloro-phenyl)-6-methyl- pyridin-2-ylamine as a brown crystalline solid. ISP mass spectrum, m/e: 253 (M+ 1 calculated for C12H1OC12N2: 253).
Example 98
In analogy to example 1, on reaction of 5-(2,4-chloro-phenyl)-6-methyl-pyridin-2- ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Dichloro- phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as an colorless waxy solid. ISn mass spectrum, m/e: 409 (M-I calculated for C18 H13Cl2FN2O2S: 409).
Example 99
In analogy to example 1, on reaction of 5-(2,4-chloro-phenyl)-6-methyl-pyridin-2- ylamine with 2,4-difluoro-benzenesulfonyl chloride there was obtained: N- [5- (2,4-
Dichloro-phenyl)-6-methyl-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide as a colorless foam. ISN mass spectrum, m/e: 427.1 (M-I calculated for C18H12Cl2F2N2O2S: 427).
Example 100 In analogy to example 1, on reaction of 5-(2,4-chloro-phenyl)-6-methyl-pyridin-2- ylamine with 4-chloro-2,5-dimethyl-benzenesulfonyl chloride there was obtained: 4- Chloro-N-[5-(2,4-dichloro-phenyl)-6-methyl-pyridin-2-yl]-2,5-dimethyl- benzenesulfonamide as a white powder. ISN mass spectrum, m/e: 453.1 (M-I calculated for C20H17Cl3N2O2S: 453).
Example 101 a) In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 2,4-dichloro-6-methyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5- (2,4-dichloro-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 458.9 (M-I calculated for Ci8H12Cl4N2O2S: 458). 94
- 59 -
Example 102 a) In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,4-dichloro- phenyl) -pyridin-2-yl]-benzenesulfonamide as an off-white foam. ISN mass spectrum, m/e: 411 (M-I calculated for Ci7H11Cl3N2O2S: 411).
Example 103 a) In analogy to example 1, on reaction of 5-(2,4-dichloro-phenyl)-pyridin-2-ylamine with 4-chloro-benzenesulfonyl chloride there was obtained: 4-Chloro-N- [5-(2,4-dichloro- phenyl)-pyridin-2-yl]-benzenesulfonamide as an off-white foam. ISP mass spectrum, m/e: 411 (M-I calculated for C17HnCl3N2O2S: 411).
Example 104 In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-6- methyl-pyridin-2-yl]-3-fluoro-benzenesulfonamide as an light-yellow foam. ISN mass spectrum, m/e: 375.2 (M-I calculated for C18 Hi4ClFN2O2S: 375).
Example 105
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2-chloro- phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as alight-yellow foam. ISN mass spectrum, m/e: 391 (M-I calculated for Ci8 Hi4Cl2N2O2S: 391).
Example 106
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 2,4-dichloro-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N-[5-(2- chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 424.9 (M-I calculated for C18 H13Cl3N2O2S: 425).
Example 107 In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 2,4-dichloro-5-methyl-benzenesulfonyl chloride there was obtained: 2,4-Dichloro-N- [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-5-methyl-benzenesulfonamide as a light- yellow foam. ISN mass spectrum, m/e: 439 (M-I calculated for Ci9 H15Cl3N2O2S: 439).
Example 108
In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-meώyl-pyridin- 2-ylamine with 3-trifluomethyl-benzenesulfonyl chloride there was obtained: N-[5-(4- Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 423 (M-I calculated for C2OH16F4N2O2S: 423).
Example 109
In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin- 2-ylamine with 2,4-dichloro-6-methyl-benzenesulfonyl chloride there was obtained: 2,4- Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 437.2 (M-I calculated for C20Hi7Cl2FN2O2S: 437).
Example 110 In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin- 2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4- fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 389 (M-I calculated for Ci9H16ClFN2O2S: 389). Example 111
In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin- 2-ylamine with 4-chloro-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5-(4- fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 389.1 (M-I calculated for C19H16ClFN2O2S: 389).
Example 112
In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin- 2-ylamine with 4-trifluoromethoxy-benzenesulfonyl chloride there was obtained: N-[5-(4- Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethoxy- benzenesulfonamide as a light-brown viscous oil. ISN mass spectrum, m/e: 439.1 (M-I calculated for C20H16F4N2O3S: 439).
Example 113 In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin- 2-ylamine with 3-methyl-benzenesulfonyl chloride there was obtained: N-[5-(4-Fluoro-2- methyl-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide as a light-yellow viscous oil. ISN mass spectrum, m/e: 369 (M-I calculated for C20H19FN2O2S: 369).
Example 114
In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin- 2-ylamine with 2-chloro-5-trifluoromethyl-benzenesulfonyl chloride there was obtained: 2-Chloro-N-[5-(4-fiuoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-5-trifluoromethyl- benzenesulfonamide as a light-yellow viscous oil. ISN mass spectrum, m/e: 457.1 (M-I calculated for C20H15ClF4N2O2S: 457).
Example 115
In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin- 2-ylamine with 4-fluoro-3-txifluoromeώyl-benzenesulfonyl chloride there was obtained: 2-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-5-trifluoromethyl- benzenesulfonamide as a light-brown viscous oil. ISN mass spectrum, m/e: 441.1 (M-I calculated for C20H15F5N2O2S: 441).
Example 116
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro-phenyl)-6- methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide as a light-yellow viscous oil. ISN mass spectrum, m/e: 371.2 (M-I calculated for C19 Hi7ClN2O2S: 371).
Example 117
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-4-fluoro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-(2- chloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a light-yellow viscous oil. ISN mass spectrum, m/e: 409.3 (M-I calculated for C18 H13Cl2FN2O2S: 409).
Example 118
In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 3-chloro-5-trifluoromethyl-benzenesulfonyl chloride there was obtained: 2-Chloro- N- [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl] -5-trifluoromethyl-benzenesulfonamide as a light-yellow viscous oil. ISN mass spectrum, m/e: 459.2 (M-I calculated for C19H13Cl2F3N2O2S: 459).
Example 119 In analogy to example 1, on reaction of 5-(2-chloro-phenyl)-6-methyl-pyridin-2-ylamine with 4-fluoro-3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2- Chloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-3-trifluoromethyl-benzenesulfonamide as a light-brown viscous oil. ISN mass spectrum, m/e: 442.9 (M-I calculated for Ci9Hi3ClF4N2O2S: 443). Example 120
In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with 3- fluoro-4-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro- phenyl) -pyridin-2-yl]-3-fluoro-4-methyl-benzenesulfonamide as a colorless solid. ISN mass spectrum, m/e: 409.1 (M-I calculated for C18H13Cl2N2O2S: 409).
Example 121
In analogy to example 1, on reaction of 5-(2,3-dichloro-phenyl)-pyridin-2-ylamine with 3,5-dimethyl-benzenesulfonyl chloride there was obtained: N- [5-(2,3-Dichloro-phenyl)- pyridin-2-yl]-3,5-dimethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 405.1 (M-I calculated for C19H16Cl2N2O2S: 405).
Example 122 a) In analogy to example 1, on reaction of 5-(5-fluoro-2-methyl-phenyl)-pyridin-2- ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N- [5- (5- Fluoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 409.1 (M-I calculated for C19Hi4F4N2O2S: 409).
Preparation of the starting material: b) In analogy to example Ib), on reaction of 5-bromo -pyridin-2-ylamine with 5-fluoro-2- methyl-phenylboronic acid there was obtained: 5-(5-fiuoro-2-methyl-phenyl)-pyridin-2- ylamine as a light yellow oil. ISP mass spectrum, m/e: 203.1 (M+ 1 calculated for
Figure imgf000064_0001
Example 123 a) In analogy to example 1, on reaction of 5-(5-fluoro-2-methyl-phenyl)-pyridin-2- ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: 4-Fluoro-N-[5-(5- fluoro-2-methyl-phenyl)-pyridin-2-yl]-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 359 (M-I calculated for C18H14F2N2O2S: 359). Example 124 a) In analogy to example 1, on reaction of 5-(5-fluoro-2-methyl-phenyl)-pyridin-2- ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro- N-[5-(5-fluoro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 389.1 (M- 1 calculated for C19H16ClFN2O2S: 389) .
Example 125 a) In analogy to example 1, on reaction of 5-(5-chloro-2-methyl-phenyl)-pyridin-2- ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N- [5- (5- Chloro-2-methyl-phenyl)-pyridin-2-yl] -3-trifluoromethyl-benzenesulfonamide as an off- white solid. ISN mass spectrum, m/e: 425.1 (M-I calculated for C19H14ClF3N2O2S: 425).
Preparation of the starting material: b) In analogy to example Ib), on reaction of 5-bromo -pyridin-2-ylamine with 5-chloro-2- methyl-phenylboronic acid there was obtained: 5-(5-chloro-2-methyl-phenyl)-pyridin-2- ylamine as a white solid. EI mass spectrum, m/e: 218.1 (M calculated for C12H11ClN2: 218).
Example 126
In analogy to example 1, on reaction of 5-(5-chloro-2-methyl-phenyl)-pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(5-Chloro-2-methyl- phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a light-yellow solid. ISN mass spectrum, m/e: 375.2 (M-I calculated for C18H14ClFN2O2S: 375).
Example 127
In analogy to example 1, on reaction of 5-(5-chloro-2-methyl-phenyl)-pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(5- chloro-2-methyl-phenyl)-pyridin-2-yl]-2-meth.yl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 405.1 (M-I calculated for C19H16Cl2N2O2S: 405).
Example 128 a) In analogy to example 1, on reaction of 5-(6-Chloro-2-fluoro-3-methyl-phenyl)- pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(6-chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl]-2-methyl- benzenesulfonamide as a white solid. ISn mass spectrum, m/e: 422.9 (M-I calculated for Ci9H15Cl2FN2O2S: 423).
Preparation of the starting material: b) In analogy to example Ib), on reaction of 5-bromo -pyridin-2-ylamine with 6-Chloro- 2-fluoro-3-methyl-phenylboronic acid there was obtained: 5-(5-chloro-2-methyl-phenyl)- pyridin-2-ylamine as awhite solid. EI mass spectrum, m/e: 237.1 (M calculated for C12H10ClFN2: 237).
Example 129
In analogy to example 1, on reaction of 5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin- 2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(6- Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as a light-yellow solid. ISN mass spectrum, m/e: 443.2 (M-I calculated for Ci9Hi3ClF4N2O2S: 443).
Example 130 In analogy to example 1, on reaction of 5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin- 2-ylamine with 4-fiuoro-benzenesulfonyl chloride there was obtained: N- [5-(6-Chloro-2- fiuoro-3-methyl-phenyl)-pyridin-2-yl]-4-fiuoro-benzenesulfonamide as a light-yellow solid. ISN mass spectrum, m/e: 393.1 (M-I calculated for C18H13ClF2N2O2S: 393). Example 131 a) In analogy to example 1, on reaction of 5-(5-Chloro-2-methyl-phenyl)-6-methyl- pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N- [5-(5-Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide as an orange oil. ISN mass spectrum, m/e: 439 (M-I calculated for C20H16ClF3N2O2S: 439).
Preparation of the starting material: b) In analogy to example Ib), on reaction of 5-bromo-6-methyl-pyridin-2-ylamine with 5- chloro-2-methyl-phenylboronic acid there was obtained: 5-(5-Chloro-2-methyl-phenyl)- 6-methyl-pyridin-2-ylamine as a white solid. ISP mass spectrum, m/e: 233 (M+ 1 calculated for C13H13ClN2: 233).
Example 132 a) In analogy to example 1, on reaction of 5-(5-Chloro-2-methyl-phenyl)-6-methyl- pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(5- Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -4-fluoro-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 389 (M-I calculated for Ci9H16ClFN2O2S: 389).
Example 133 a) In analogy to example 1, on reaction of 5-(5-Chloro-2-methyl-ρhenyl)-6-methyl- pyridin-2-ylamine with 3-chloro-2-methyl-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(5-chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl- benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 419 (M-I calculated for C20H18Cl2N2O2S: 419).
Example 134 a) In analogy to example 1, on reaction of 5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6- methyl-pyridin-2-ylamine with 3-trifiuoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(6-Chloro-2-fiuoro-3-methyl-phenyl)-6-methyl-pyridin-2-yl]-3- trifluoromethyl-benzenesulfonamide as a light-yellow solid. ISN mass spectrum, m/e: 457.2 (M-I calculated for C20H15ClF4N2O2S: 457).
Preparation of the starting material b) In analogy to example Ib), on reaction of 5-bromo -6-methyl-pyridin-2-ylamine with 6-Chloro-2-fluoro-3-methyl-phenylboronic acid there was obtained: 5-(5-chloro-2- methyl-phenyl)-6-methyl-pyridin-2-ylamine as which was used without further purification in the next reaction step.
Example 135
In analogy to example 1, on reaction of 5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6-methyl- pyridin-2-ylamine with 4-fiuoro-benzenesulfonyl chloride there was obtained: N-[5-(6- Chloro-2-fluoro-3-methyl-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 407.2 (M-I calculated for Ci9H15ClFN2O2S: 407).
Example 136
In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamine with 4-chloro-benzenesulfonyl chloride there was obtained: 4-Chloro-N-[5-(4-fluoro-2- metfiyl-phenyl)-pyridin-2-yl] -benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 375.2 (M-I calculated for C18H14ClFN2O2S: 375).
Example 137
In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4-fluoro-2- methyl-phenyl)-pyridin-2-yl] -benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 375.2 (M-I calculated for C18Hi4ClFN2O2S: 375). Example 138 a) In analogy to example 1, on reaction of 5-(4-fluoro-2-methyl-phenyl)-pyridin-2- ylamine with 2,4-dichloro-5-methyl-benzenesulfonyl chloride there was obtained: 2,4- Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 422.9 (M-I calculated for C19H15Cl2FN2O2S: 423).
Example 139 a) In analogy to example 1, on reaction of 5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2- ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,5- dichloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a light-yellow solid. ISN mass spectrum, m/e: 425 (M-I calculated for C1SHBCISN2O2S: 425).
Preparation of the starting material: b) In analogy to example Ib), on reaction of 5-bromo -6-methyl-pyridin-2-ylamine with 2,5-dichloro-phenylboronic acid there was obtained: 5-(2,5-Dichloro-phenyl)-6-methyl- pyridin-2-ylamine as white solid. EI mass spectrum, m/e: 252.1 (M calculated for
Figure imgf000069_0001
Example 140 a) In analogy to example 1, on reaction of 5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2- ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,5-Dichloro- phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 409 (M-I calculated for Ci8Hi3Cl2FN2O2S: 409).
Example 141 a) In analogy to example 1, on reaction of 5-(5-Fluoro-2-methyl-phenyl)-6-methyl- pyridin-2-ylamine with 3-txifluoro-benzenesulfonyl chloride there was obtained: N- [5- (5- Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as an off-white solid. ISN mass spectrum, m/e: 422.9 (M-I calculated for
Figure imgf000070_0001
423).
Preparation of the starting material: b) In analogy to example Ib), on reaction of 5-bromo -6-methyl-pyridin-2-ylamine with 5-fluoro-2-methyl-phenylboronic acid there was obtained: 5-(5-Fluoro-2-methyl-phenyl)- 6-methyl-pyridin-2-ylamine a light-yellow oil. EI mass spectrum, m/e: 216.2 (M calculated for C13H13FN2: 216).
Example 142 a) In analogy to example 1, on reaction of 5-(5-Fluoro-2-methyl-phenyl)-6-methyl- pyridin-2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: 4-Fluoro- N-[5-(5-fluoro-2-methyl-phen7l)-6-methyl-pyridin-2-yl]-benzenesulfonamide as an off- white solid. ISN mass spectrum, m/e: 373.1 (M-I calculated for C19H16F2N2O2S: 373).
Example 143 a) In analogy to example 1, on reaction of 5-(5-Fluoro-2-methyl-phenyl)-6-methyl- pyridin-2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro- N- [5-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -benzenesulfonamide as an off- white solid. ISN mass spectrum, m/e: 389 (M-I calculated for C19H16ClFN2O2S: 389).
Example 144 a) In analogy to example 1, on reaction of 5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2- ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N- [5-(2,5- Dichloro-phenyl)-6-methyl-pyridin-2-yl] -3-trifluoromethyl-benzenesulfonamide as an orange oil. ISN mass spectrum, m/e: 459 (M-I calculated for C19H13Cl2F3N2O2S: 459).
Example 145 a) In analogy to example 1, on reaction of 5-(2-CHoro-4-fluoro-phenyl)-6-methyl- pyridin-2-ylamine with 3-trifluoro-benzenesulfonyl chloride there was obtained: N-[5-(2- Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as an light-yellow solid. ISN mass spectrum, m/e: 442.9 (M-I calculated for Ci9Hi3ClF4N2O2S: 443).
Preparation of the starting material: b) In analogy to example Ib), on reaction of 5-bromo-6-methyl-pyridin-2-ylamine with 2- chloro-4-fiuoro-phenylboronic acid there was obtained: 5-(2-Chloro-4-fiuoro-phenyl)-6- methyl-pyridin-2-ylamine an off-white soli. EI mass spectrum, m/e: 236.1 (M calculated for Ci2HioClFN2: 236).
Example 146
In analogy to example 1, on reaction of 5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin- 2-ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N- [5-(2-Chloro-4- fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 392.9 (M-I calculated for C18Hi3ClF2N2O2S: 393).
Example 147
In analogy to example 1, on reaction of 5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin- 2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2- chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 409 (M-I calculated for Ci8Hi3Cl2FN2O2S: 409).
Example 148 a) In analogy to example 1, on reaction of 5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2- ylamine with 3-trifluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,3- Dichloro-phenyl)-6-methyl-pyridin-2-yl] -3-trifiuoromethyl-benzenesulfonamide as a light-yellow amorphous solid. ISN mass spectrum, m/e: 459.2 (M-I calculated for Ci9Hi3Cl2F3N2O2S: 459).
Preparation of the starting material: b) In analogy to example Ib), on reaction of 5-bromo-6-methyl-pyridin-2-ylamine with 2,3-dichloro -phenylboronic acid there was obtained: 5-(2,3-Dichloro~phenyl)-6-methyl- pyridin-2-ylamine an off-white solid. EI mass spectrum, m/e: 252.1 (M calculated for
Figure imgf000072_0001
Example 149 a) In analogy to example 1, on reaction of 5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2- ylamine with 4-fiuoro-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro- phenyl)-6-metihyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 409.3 (M-I calculated for C18Hi3Cl2FN2O2S: 409).
Example 150
In analogy to example 1, on reaction of 5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2- ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2,3- dichloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 425.1 (M-I calculated for Ci8Hi3Cl3N2O2S: 425).
Example 151
In analogy to example 1, on reaction of 5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2- ylamine with 2,4-dichloro-6-methyl-benzenesulfonyl chloride there was obtained: 2,4- Dichloro-N-[5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide as an off-white foam. ISN mass spectrum, m/e: 473.1 (M-I calculated for Ci9Hi4Cl4N2O2S: 473).
Example 152 In analogy to example 1, on reaction of 5-(2>3-Dichloro-phenyl)-6-methyl-pyridin-2- ylamine with 3-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,3-Dichloro- phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 405.3 (M-I calculated for C19H16Cl2N2O2S: 405).
Example 153 a) In analogy to example 1, on reaction of 5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2- ylamine with 2,4-dichloro-6-methyl-benzenesulfonyl chloride there was obtained: 2,4- Dichloro-N-[5-(2)5-dichloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 475 (M-I calculated for Ci9H14Cl4F3N2O2S: 475).
Example 154
In analogy to example 1, on reaction of 5-(2-CHoro-4-fluoro-phenyl)-6-methyl-pyridin- 2-ylamine with 3-methyl-benzenesulfonyl chloride there was obtained: N- [5-(2-Chloro-4- fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 389 (M-I calculated for C19Hi6ClFN2O2S: 389).
Example 155 In analogy to example 1, on reaction of 5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin- 2-ylamine with 2,4-dichloro-5-methyl-benzenesulfonyl chloride there was obtained: 2,4- Dichloro-N- [5- (2-chloro-4-fluoro-phenyl) -6-methyl-pyridin-2-yl] -6-methyl- benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 457.1 (M-I calculated for C19Hi4Cl3FN2O2S: 457).
Example 156
In analogy to example 1, on reaction of 5-(2,4-bis-trifluoromethyl-phenyl)-pyridin-2- ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Bis- trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 479 (M-I calculated for C19HnClF6N2O2S: 479). Example 157
In analogy to example 1, on reaction of 5-(2,4-bis-trifluoromethyl-phenyl)-pyridin-2- ylamine with 3-methyl-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Bis- trifluoromethyl-phenyl)-pyridin-2-yl]-3-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 459.1 (M-I calculated for C20H14F6N2O2S: 459).
Example 158 In analogy to example 1, on reaction of 5-(2,4-bis-trifluoromethyl-phenyl)-pyridin-2- ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,4-Bis- trifluoromethyl-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 463 (M-I calculated for C20H11F7N2O2S: 463).
Example 159
In analogy to example 1, on reaction of 5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2- ylamine with 4-fluoro-3-trifluoro-benzenesulfonyl chloride there was obtained: N-[5-(2,3- Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-3-trifluoromethyl- benzenesulfonamide as an off-white foam. ISN mass spectrum, m/e: 476.9 (M-I calculated for Ci9H12Cl2F4N2O2S: 477).
Example 160
In analogy to example 1, on reaction of 5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2- ylamine with 3-chloro-4-fhioro-benzenesulfonyl chloride there was obtained: 3-Chloro-N- [5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl] -4-fluoro-benzenesulfonamide as an off- white foam. ISN mass spectrum, m/e: 442.9 (M-I calculated for Ci8H12Cl3FN2O2S: 443).
Example 161 a) In analogy to example 1, on reaction of 5-(2-Fluoro-phenyl)-6-methyl-pyridin-2- ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2- fluoro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide as an off-white foam. ISN mass spectrum, m/e: 375.2 (M-I calculated for C18H14ClFN2O2S: 375).
Preparation of the starting material: b) In analogy to example Ib), on reaction of 5-bromo-6-methyl-pyridin-2-ylamine with 2- fiuoro-phenylboronic acid there was obtained: -(2-Fluoro-phenyl)-6-methyl-pyridin-2- ylamine an off-white solid. EI mass spectrum, m/e: 202.2(M calculated for C12H11FN2: 202).
Example 162 a) In analogy to example 1, on reaction of 5-(2-Fluoro-phenyl)-6-methyl-ρyridin-2- ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: 4-Fluoro-N-[5-(2- fluoro-phenyl)-6-methyl-pyridin-2-yl] -benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 359 (M-I calculated for C18H14F2N2O2S: 359).
Example 163 a) In analogy to example 1, on reaction of 5-(2-Fluoro-phenyl)-6-methyl-pyridin-2- ylamine with 4-fluoro-3-trifluoromethyl-benzenesulfonyl chloride there was obtained: 4- Fluoro-N-[5-(2-fluoro-ρhenyl)-6-methyl-pyridin-2-yl]-3-trifiuoromethyl- benzenesulfonamide as a white foam. ISN mass spectrum, m/e: 427.1(M-I calculated for
Figure imgf000075_0001
Example 164
In analogy to example 1, on reaction of 5-(2,4-bis-trifluoromethyl-phenyl)-pyridin-2- ylamine with 3-chloro-4-fiuoro-benzenesulfonyl chloride there was obtained: N-[5-(2,4- Bis-trifluoromethyl-phenyl)-pyridin-2-yl] -3-chloro-4-fluoro-benzenesulfonamide as an off-white foam. ISN mass spectrum, m/e: 496.9 (M-I calculated for Ci9Hi0ClF7N2O2S: 497) Example 165
In analogy to example 1, on reaction of 5-(2-Fluoro-phenyl)-6-memyl-pyridin-2-ylamine with 2,4-dichloro-6-methyl-3-benzenesulfonyl chloride there was obtained: 2,4-Dichloro- N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide as an off- white foam. ISN mass spectrum, m/e: 422.9 (M-I calculated for C19H15Cl2FN2O2S: 423).
Example 166
In analogy to example 1, on reaction of 5-(2-Fluoro-phenyl)-6-methyl-pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2-Fluoro- phenyl) -6-methyl-pyridin-2-yl] -3-trifluoromethyl-benzenesulfonamide as a light-yellow foam. ISN mass spectrum, m/e: 409.1 (M-I calculated for C19H14F4N2O2S: 409).
Example 167 a) In analogy to example 1, on reaction of 5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2- ylamine with 3-trifluoro-benzenesulfonyl chloride there was obtained: N- [5-(2-Chloro- phenyl)-3,4-dimethyl-pyridin-2-yl] -3-tτifluoromethyl-benzenesulfonamide as a yellow amorphous solid. ISN mass spectrum, m/e: 439.1 (M-I calculated for C20H16ClFsN2O2S: 439).
Preparation of the starting material: b) In analogy to example Ib), on reaction of 5-bromo-3,4-dimethyl-pyridin-2-ylamine with 2-chloro-phenylboronic acid there was obtained: 5-(2-Chloro-phenyl)-3,4-dimethyl- pyridin-2-ylamine a white solid. ISP mass spectrum, m/e: 233 (M+ 1 calculated for C13H13ClN2: 233).
Example 168 a) In analogy to example 1, on reaction of 5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2- ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2- chloro-phenyl)-3,4-dimethyl-pyridin-2-yl]-benzenesulfonamide as a yellow amorphous solid. ISN mass spectrum, m/e: 405.1 (M- 1 calculated for C19H16Cl2N2O2S: 405) . Example 169
In analogy to example 1, on reaction of 5-(2-CHoro-phenyl)-3,4-dimethyl-pyridin-2- ylamine with 4-fluoro-benzenesulfonyl chloride there was obtained: N-[5-(2-Chloro- phenyl) -3,4-dimethyl-pyridin-2-yl] -4-fluoro-benzenesulfonamide as a yellow amorphous solid. ISN mass spectrum, m/e: 389 (M-I calculated for C19Hi6ClFN2O2S: 389).
Example 170 a) In analogy to example 1, on reaction of 2-Methyl-[3,3']bipyridinyl-6-ylamine with 3- trifluoro-benzenesulfonyl chloride there was obtained: N-(2-Methyl-[3,3']bipyridinyl-6- yl)-3-trifluoromethyl-benzenesulfonamide as a light-yellow amorphous solid. ISN mass spectrum, m/e: 392(M-I calculated for Ci8Hi4F3N3O2S: 392).
Preparation of the starting material: b) In analogy to example Ib), on reaction of 5-bromo-6-methyl-pyridin-2-ylamine with 3- pyridylboronic acid there was obtained: 2-Methyl-[3,3']bipyridinyl-6-ylamine a yellow solid. EI mass spectrum, m/e: 185.2 (M calculated for Ci1Hi1Na: 185).
Example 171 a) In analogy to example 1, on reaction of 5-(2-Chloro-phenyl)-4-methyl-pyridin-2- ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(2- chloro-phenyl)-4-methyl-pyridin-2-yl]-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 391 (M-I calculated for Ci8Hi4Cl2N2O2S: 391).
Preparation of the starting material: b) In analogy to example Ib), on reaction of 5-bromo-4-methyl-pyridin-2-ylamine with 2- chloro-phenylboronic acid there was obtained: 5-(2-Chloro-phenyl)-4-methyl-ρyridin-2- ylamine a yellow solid. EI mass spectrum, m/e: 218.1 (M calculated for CI2HHCIN2: 218). Example 172 a) In analogy to example 1, on reaction of 5-(2-Chloro-phenyl)-4-methyl-pyridin-2- ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N-[5-(2- Chloro-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide as an off- white solid. ISN mass spectrum, m/e: 425.1 (M-I calculated for C19H14ClF3N2O2S: 425).
Example 173 a) In analogy to example 1, on reaction of 5-(2-Chloro-phenyl)-4-methyl-pyridin-2- ylamine with 2,4-dichloro-6-methyl-benzenesulfonyl chloride there was obtained: 2,4- Dichloro-N-[5-(2-chloro-phenyl)-4-methyl-pyridin-2-yl]-6-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 439 (M-I calculated for C19H15Cl3N2O2S: 439).
Example 174 In analogy to example 1, on reaction of 2-Methyl- [3,3']bipyridinyl-6-ylamine with 3- chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-(2-methyl- [3,3']bipyridinyl-6-yl)-benzenesulfonamide as a light-brown amorphous solid. ISN mass spectrum, m/e: 358 (M-I calculated for C17H14ClN3O2S: 358).
Example 175
In analogy to example 1, on reaction of 5-(4-Fluoro-2-methyl-phenyl)-4-methyl-pyridin- 2-ylamine with 3-chloro-benzenesulfonyl chloride there was obtained: 3-Chloro-N-[5-(4- fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-benzenesulfonamide as a colorless solid. ISN mass spectrum, m/e: 389 (M-I calculated for C19H16ClFN2O2S: 389).
Preparation of the starting material: b) In analogy to example Ib), on reaction of 5-bromo-4-methyl-pyridin-2-ylamine with 2- chloro-phenylboronic acid there was obtained: 5-(4-Fluoro-2-methyl-phenyl)-4-methyl- pyridin-2-ylamine as an amorphous light-yellow solid. ISP mass spectrum, m/e: 217.3 (M+l calculated for C13Hi3FN2: 217).
Example 176 a) In analogy to example 1, on reaction of 5-(4-Fluoro-2-methyl-phenyl)-4-methyl- pyridin-2-ylamine with 3-trifluoromethyl-benzenesulfonyl chloride there was obtained: N- [5-(4-Fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 423 (M-I calculated for C20H16F4N2O2S: 423).
Example 177 a) In analogy to example 1, on reaction of 5-(4-Fluoro-2-methyl-phenyl)-4-methyl- pyridin-2-ylamine with 2,4-dichloro-6-methyl-trifluoromethyl-benzenesulfonyl chloride there was obtained: 2)4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyridin-2- yl] -6-methyl-benzenesulfonamide as a white solid. ISN mass spectrum, m/e: 437.2(M-I calculated for C20H17Cl2FN2O2S: 437).
Example A
A compound of formula I can be used in a manner known per se as the active ingredient for the production of tablets of the following composition:
Per tablet
Active ingredient 200 mg
Microcrystalline cellulose 155 mg
Corn starch 25 mg Talc 25 mg
Hydroxypropylmethylcellulose 20 mg
425 mg Example B
A compound of formula I can be used in a manner known per se as the active ingredient for the production of capsules of the following composition:
Per capsule
Active ingredient 100.0 mg
Corn starch 20.0 mg
Lactose 95.0 mg Talc 4.5 mg
Magnesium stearate 0.5 mg 220.0 mg

Claims

1. Compounds of formula
Figure imgf000081_0001
(0 wherein
R1 is hydrogen, alkyl, cycloalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, amino or aminoalkyl;
R2 is hydrogen, alkyl or halogen;
R3 is hydrogen, alkyl or halogen;
R4 is phenyl, naphtyl, thiophenyl, pyridyl, quinolyl, piperidyl, morpholyl or thiomorpholyl optionally substituted with one or more substituents independently selected from alkyl, cycloalkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, cyano, trifluoromethyl, trifiuoromethoxy, aryl, arylalkyl, aryloxy, heterocyclyl, alkylcarbonylamino, alkoxycarbonylalkoxy and alkyl-SO2- ;
R5 is hydrogen or alkyl;
R6, R7, R8, R9 and R10 are independently selected from hydrogen, alkyl, halogen, cyano, trifluoromethyl, alkoxy and alkyl-SO2-;
A is nitrogen or C-R10;
E is nitrogen or C-R9; G is nitrogen or C-R8;
wherein not more than one of A, E and G is nitrogen;
and pharmaceutically acceptable salts and esters thereof.
2. Compounds according to claim 1, wherein R1 is hydrogen.
3. Compounds according to claim 1, wherein R1 is alkyl.
4. Compounds according to any one of claims 1 to 3, wherein R2 is hydrogen.
5. Compounds according to any one of claims 1 to 3, wherein R2 is alkyl.
6. Compounds according to any one of claims 1 to 5, wherein R3 is hydrogen.
7. Compounds according to any one of claims 1 to 6, wherein R3 is alkyl.
8. Compounds according to any one of claims 1 to 7, wherein R5 is hydrogen.
9. Compounds according to any one of claims 1 to 8, wherein A is C-R1 .
10. Compounds according to any one of claims 1 to 9, wherein E is C-R .
11. Compounds according to any one of claims 1 to 9, wherein E is nitrogen.
12. Compounds according to any one of claims 1 to 11, wherein G is C-R8.
13. Compounds according to any one of claims 1 to 12, wherein R4 is phenyl optionally substituted with one to three substituents independently selected from alkyl, cycloalkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, cyano, trifluoromethyl, trifluoromethoxy, aryl, arylalkyl, aryloxy, heterocyclyl, alkylcarbonylamino, alkoxycarbonylalkoxy and alkyl-SO2-.
14. Compounds according to claim 13, wherein R4 is phenyl substituted with one to three substituents independently selected from alkyl, halogen and trifluoromethyl.
15. Compounds according to any one of claims 1 to 14, wherein R6, R7, R8, R9 and R10 are independently selected from hydrogen, alkyl, halogen and trifluoromethyl.
16. Compounds according to any one of claims 1 to 15, wherein R6 is halogen, alkyl or trifluoromethyl.
17. Compounds according to claim 16, wherein R6 is chloro, methyl or trifluoromethyl.
18. Compounds according to any one of claims 1 to 17 selected from
N- [5-(2-Chloro-phenyl)-pyridin-2-yl] -5-fiuoro-2-methyl-benzenesulfonamide;
3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
3-Chloro-N- [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl] -2-methyl- benzenesulfonamide;
Biphenyl-4-sulfonic acid [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-amide;
3-Chloro-N- [5-(2-chloro-4-fluoro-phenyl)-pyridin-2-yl] -2-methyl- benzenesulfonamide;
3-Chloro-N-[5-(3-fluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
3-Chloro-N- [5-(2,4-difluoro-phenyl)-pyridin-2-yl] -2-methyl-benzenesulfonamide;
N-[5-(2,4-Difiuoro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
3-Chloro-N-[5-(4-methoxy-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
3-Chloro-N- [5-(4-fluoro-phenyl)-pyridin-2-yl] -2-methyl-benzenesulfonamide;
5-Fluoro-N-[5-(4-fluoro-phenyl)-pyridin-2-yl] -2-methyl-benzenesulfonamide;
5-Fluoro-N-[5-(2-methoxy-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
3-Chloro-N- [5- (2-fluoro-phenyl) -pyridin-2-yl] -2-methyl-benzenesulfonamide;
5-Fluoro-N-[5-(2-fluoro-phenyl)-pyxidin-2-yl]-2-methyl-benzenesulfonamide;
2,4-Dichloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-6-methyl-benzenesulfonamide; N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-2,5-difluoro-benzenesulfonamide;
3-Chloro-N-[5-(4-methanesulfonyl-phenyl)-pyridin-2-yl]-2-methyl- benzenesulfonamide;
3-Chloro-N- [5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl] -2-methyl- benzenesulfonamide;
5-Fluoro-N- [5-(4-fluoro-phenyl) -6-methyl-pyridin-2-yl] -2-methyl- benzenesulfonamide;
3-Chloro-N- [5-(3-fluoro-phenyl)-6-methyl-pyridin-2-yl] -2-methyl- benzenesulfonamide;
5-Fluoro-N-[5-(3-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methyl- benzenesulfonamide;
N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-3,4-dimethoxy-benzenesulfonamide;
3,4-Dichloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl] -benzenesulfonamide;
N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-2,5-difluoro-benzenesulfonamide;
3-Chloro-N- [5-(2,3-dichloro-phenyl)-pyridin-2-yl] -2-methyl-benzenesulfonamide;
3,4-Dichloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-benzenesulfonamide;
N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-3,4-dimethoxy-benzenesulfonamide;
3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yi]-4-methyl-benzenesulfonamide;
5-Fluoro-N- [5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl] -2-methyl- benzenesulfonamide;
3-Chloro-N- [5-(4-fluoro-2-methyl-phenyl)-pyridm-2-yl] -2-methyl- benzenesulfonamide;
3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-4-methoxy-benzenesulfonamide;
4,5-Dichloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2-fluoro-benzenesulfonamide; 3-Chloro-N- [5-(2,4-dichloro-phenyl)-pyridin-2-yl] -4-methoxy- beπzenesulfonamide;
3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
Piperidine- 1 -sulfonic acid [5-(2,4-dichloro-phenyl)-pyridin-2-yl] -amide;
N- [5-(2,3-Dichloro-phenyl)-pyridin-2-yl] -2-trifluoromethyl-benzenesulfonamide;
N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
N- [5- (2,5-Dichloro-phenyl)-pyridin-2-yl] -2,5-difluoro-benzenesulfonamide;
N-[5-(2,5-Dichloro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
3-Chloro-N-[5-(2,5-dichloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
5-Fluoro-N- [5-(2-fluoro-5-trifluoromethyl-phenyl)-pyridin-2-yl] -2-methyl- benzenesulfonamide;
3-Chloro-N- [ 5- (2-fluoro-5-trifluoromeώyl-phenyl) -pyridin-2-yl] -2-methyl- beπzenesulfonamide;
3-Chloro-2-methyl-N-[5-(2-trifluoromethyl-phenyl)-pyridin-2-yl]- benzenesulfonamide;
3-Chloro-4-methyl-N- [5-(2-trifluoromethyl-phenyl)-pyridin-2-yl] - benzenesulfonamide;
5-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2-methoxy'- benzenesulfonamide;
N-{2-Chloro-4- [5-(2,4-dichloro-phenyl)-pyridin-2-ylsulfamoyl] -phenyl}- acetamide;
N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide;
N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-methysulfonyl-benzenesulfonamide;
3-Chloro-N-[5-(2,3-difluoro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide; N-[5-(2,3-Difluoro-phenyl)-pyridin-2-yl]-5-fluoro-2-methyl-benzenesulfonamide;
N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-2-methyl- b enzenesulfonamide;
N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-4-methyl- b enzenesulfonamide;
3-Chloro-N-[5-(2,3-difluoro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
Piperidine-1 -sulfonic acid [5-(2,3-dichloro-phenyl)-pyridin-2-yl] -amide;
5-Chloro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2-methoxy- benzenesulfonamide;
N-{2-Chloro-4- [5-(4-fluoro-ρhenyl)-6-methyl-pyridin-2-ylsulfamoyl] -phenyl}- acetamide;
N- [5-(4-Fluoro-phenyl)-6-methyl-pyridin-2-yl] -4-trifluoromethyl- benzenesulfonamide;
N- [5-(4-Fluoro-phenyl)-6-methyl-pyridin-2-yl] -4-methanesulfonyl- benzenesulfonamide;
{4-[5-(2,3-Dichloro-phenyl)-pyridin-2-ylsulfamoyl]-phenoxy}-acetic acid methyl ester;
N-[5-(4-Fluoro-phenyl)-6-methyl-pyridin-2-yl]-4-trifluoromethoxy- benzenesulfonamide;
3-Chloro-N-[5-(4-fluoro-phenyl)-6-methyl-pyτidin-2-yl]-4-methoxy- benzenesulfonamide;
4-Chloro-N-[5-(4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-2,5-dimethyl- benzenesulfonamide;
N- [5- (2,3-Dichloro-phenyl) -pyridin-2-yl] -4- (2-hydroxy-ethox7) - benzenesulfonamide;
N-[5-(2-Chloro-phenyi)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide; 3-Chloro-N- [5-(2-chloro-pheπyl)-6-methyl-pyridin-2-yl] -4-methyl- benzenesulfonamide;
4-Chloro-N- [5- (2-chloro-phenyl)-6-methyl-pyridin-2-yl] -benzenesulfonamide;
2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide;
Piperidine-1-sulfonic acid [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-amide;
N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
4-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2,5-dimethyl- benzenesulfonamide;
N- [5-(2,4-Dichloro-phenyl)-pyridin-2-yl] -2,4-difluoro-benzenesulfonamide;
2,4-Dichloro-N- [5-(2,4-dichloro-phenyl)-pyridin-2-yl] -5-methyl- benzenesulfonamide;
N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide
4-Fluoro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]- benzenesulfonamide;
3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl- benzenesulfonamide;
5-Fluoro-N- [ 5- (4-fluoro-2-methyl-phenyl) -6-methyl-pyridin-2-yl] -2-methyl- benzenesulfonamide;
3-Chloro-N- [5-(2,3-dichloro-pheπyl)-pyridin-2-yl] -4-methyl-benzenesulfonamide;
N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-4-trifluoromethyl-benzenesulfonamide;
3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-methyl- benzenesulfonamide;
N-[5-(4-Fluoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluorometliyl- benzenesulfonamide; N- [5-(4-Fluoro-2-methyl-phenyl)-pyridin-2-yl] -4-trifluoromethyl- benzenesulfonamide;
N- [ 5- (2-Chloro-phenyl) -pyridin-2-yl] -3 -trifluoromethyl-benzenesulfonamide;
N- [5-(2-Chloro-phenyl)-pyridin-2-yl] -4-ethyl-benzenesulfonamide;
3-Chloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-benzenesulfonamide;
3-Chloro-N-[5-(2J4-dichloro-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonaniide;
N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl] -4-ethyl-benzenesulfonamide;
N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-3-trifluoromethyl-benzenesulfonamide;
N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide;
N- [5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl] -4-trifluoromethoxy- benzenesulfonamide;
N- [5-(2-Chloro-phenyl)-pyridin-2-yl] -4-fluoro-benzenesulfonamide;
N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
4-Chloro-N- [5-(2-chloro-phenyl)-pyridin-2-yl] -2,5-dimethyl-benzenesulfonamide;
4-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-2,5-dimethyl- benzenesulfonamide;
N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
3,5-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
N- [5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
N-[5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
N- [5-(2,4-Dichloro-pb.enyl)-6-methyl-pyridin-2-yl] -2,4-difluoro- benzenesulfonamide; 4-Chloro-N-[5-(2,4-dichloro-phenyl)-6-methyl-pyridin-2-yl]-2,5-dimethyl- benzenesulfonamide;
2,4-Dichloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-6-meth.yl- beπzenesulfonamide;
3-Chloro-N- [5-(2,4-dichloro-phenyl)-pyridin-2-yl] -benzenesulfonamide;
4-Chloro-N[5-(2,4-dichloro-phenyl)-pyτidin-2-yl]-benzenesulfonamide;
N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-3-fluoro-benzenesulfonamide;
3-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
2,4-Dichloro-N-[5-(2-chloro-ρhenyl)-6-meth.yl-pyridin-2-yl] -benzenesulfonamide;
2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-5-methyl- benzenesulfonamide;
N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoronietb.yl- benzenesulfonamide;
2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide;
3-Chloro-N- [5-(4-nuoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] - benzenesulfonamide;
4-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]- benzenesulfonamide;
N- [5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -4-trifluoromethoxy- benzenesulfonamide;
N- [5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -3-methyl- benzenesulfonamide;
2-Chloro-N- [5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -5- trifiuoromethyl-benzenesulfonamide; 4-Fluoro-N-[5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3- trifluoromethyl-benzenesulfonamide;
N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide;
3-Chloro-N-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro- benzenesulfonamide;
2-Chloro-N- [5- (2-chloro-phenyl)-6-methyl-pyridin-2-yl] -5-trifluoromethyl- benzenesulfonamide;
N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-3-trifluoromethyl- benzenesulfonamide;
N- [5- (2,3-Dichloro-phenyl)-pyridin-2-yl] -3-fluoro-4-methyl-benzenesulfonamide;
N-[5-(2,3-Dichloro-phenyl)-pyridin-2-yl]-3,5-dimethyl-benzenesulfonamide;
N- [5-(5-Fluoro-2-methyl-phenyl)-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
4-Fluoro-N-[5-(5-fluoro-2-methyl-phenyi)-pyτidin-2-yl]-benzenesulfonamide;
3-Chloro-N- [5-(5-fluoro-2-methyl-phenyl)-pyridin-2-yl] -2-methyl- benzenesulfonamide;
N-[5-(5-Chloro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide;
N-[5-(5-Chloro-2-methyl-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
3-Chloro-N-[5-(5-chloro-2-methyl-phenyl)-pyridin-2-yl]-2-methyl- benzenesulfonamide;
3-Chloro-N-[5-(6-chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl]-2-methyl- benzenesulfonamide;
N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl]-3-trifluorometh.yl- benzenesulfonamide; N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-ρyridin-2-yl]-4-fluoro- benzenesulfonamide;
N- [ 5- (5-Chloro-2-methyl-phenyl) -6-methyl-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
N- [5-(5-Chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -4-fluoro- benzenesulfonamide;
3-Chloro-N-[5-(5-chloro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-2-methyl- benzenesulfonamide;
N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6-methyl-pyridin-2-yl]-3- trifluoromethyl-benzenesulfonamide;
N-[5-(6-Chloro-2-fluoro-3-methyl-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro- benzenesulfonamide;
4-Chloro-N- [5- (4-fluoro-2-methyl-phenyl) -pyridin-2-yl] -benzenesulfonamide;
3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-benzenesulfonamide;
2,4-Dichloro-N- [5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl] -6-methyl- benzenesulfonamide;
3-Chloro-N-[5-(2,5-dichloro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
N-[5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
N-[5-(5-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide;
4-Fluoro-N- [5-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] - benzenesulfonamide;
3-Chloro-N- [5-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] - benzenesulfonamide;
N- [5-(2,5-Dichloro-phenyl)-6-methyl-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide; N-[5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide;
N- [5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl] -4-fluoro- benzenesulfonamide;
3-Chloro-N- [5-(2-chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl] - benzenesulfonamide;
N-[5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide;
N-[5-(2,3-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
3-Chloro-N- [5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl] -benzenesulfonamide;
2,4-Dichloro-N-[5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide;
N-[5-(2)3-Dichloro-phenyl)-6-methyl-pyridin-2-yl]-3-methyl-benzenesulfonamide;
2,4-Dichloro-N-[5-(2,5-dichloro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide;
N- [5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl] -3-methyl- benzenesulfonamide;
2)4-Dichloro-N-[5-(2-chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide;
N-[5-(2,4-Bis-trifl.uoromethyl-phenyl)-pyridin-2-yl]-3-chloro-benzenesulfonamide;
N-[5-(2,4-Bis-trifluoromethyl-phenyi)-pyridin-2-yl]-3-methyl-benzenesulfonamide;
N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
N-[5-(2,3-Dichloro-phenyl)-6-meth.yl-pyridm-2-yl]-4-fluoro-3-trifluoromethyl- benzenesulfonamide;
3-Chloro-N- [5-(2,3-dichloro-phenyl)-6-methyl-pyridin-2-yl] -4-fluoro- benzenesulfonamide; 3-Chloro-N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
4-Fluoro-N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-benzenesulfonamide;
4-Fluoro-N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-tri£luoromethyl- benzenesulfonamide;
N- [5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl] -3-chloro-4-fluoro- b enzenesulfonamide;
2)4-Dichloro-N-[5-(2-fluoro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide;
N-[5-(2-Fluoro-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide;
N- [5- (2-Chloro-phenyl)-3,4-dimethyl-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
3-Chloro-N-[5-(2-chloro-phenyl)-3,4-dimethyl-pyridin-2-yl] -benzenesulfonamide;
N-[5-(2-Chloro-phenyl)-3,4-dimethyl-pyridin-2-yl]-4-fluoro-benzenesulfonamide;
N-(2-Methyl-[3,3']bipyridinyl-6-yl)-3-trifluoromethyl-benzenesulfonamide;
3-Chloro-N-[5-(2-chloro-phenyl)-4-methyl-pyridin-2-yl]-benzenesulfonamide;
N-[5-(2-Chloro-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide;
2,4-Dichloro-N-[5-(2-chloro-phenyl)-4-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide;
3-Chloro-N-(2-methyl-[3)3']bipyτidinyl-6-yl)-benzenesulfonamide;
3-Chloro-N-[5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyτidin-2-yl]- benzenesulfonamide;
N-[5-(4-Fluoro-2-meth.yl-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyi- benzenesulfonamide; and 2,4-DicUoro-N-[5-(4-fluoro-2-meiliyl-phenyl)-4-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide.
19. Compounds according to any one of claims 1 to 18 selected from
N-[5-(2-Chloro-phenyl)-pyridin-2-yl]-5-fluoro-2-metliyl-benzenesulfonamide;
3-Chloro-N- [5-(2-chloro-phenyl)-pyridin-2-yl] -2-methyl-benzenesulfonamide;
3-Chloro-N-[5-(2,4-dichloro-phenyl)-pyridin-2-yl]-2-methyl-benzenesulfonamide;
3-Chloro-N- [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl] -2-methyl- benzenesulfonamide;
4,5-Dichloro-N-[5-(2-chloro-phenyl)-pyridin-2-yl]-2-fluoro-benzenesulfonamide;
3-Chloro-N- [5-(2,4-dichloro-phenyl)-pyridin-2-yl] -4-methyl-benzenesulfonamide;
Piperidine-1 -sulfonic acid [5-(2,4-dichloro-phenyl)-pyridin-2-yl]-amide;
N- [5-(2,3-Dichloro-phenyl) -pyridin-2-yl] -4-fluoro-benzenesulfonamide;
3-Chloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl]-4-methyl- benzenesulfonamide;
4-Chloro-N- [5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl] -benzenesulfonamide;
2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-meth.yl-pyridin-2-yl]-6-methyl- benzenesulfonamide;
N- [ 5- (2,4-Dichloro-phenyl) -pyridin-2-yl] -4-fluoro-benzenesulfonamide;
N-[5-(2,4-Dichloro-phenyl)-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
3-Chloro-N- [5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -2-methyl- benzenesulfonamide;
3-Chloro-N-[5-(2,3-dichloro-phenyl)-pyridin-2-yl]-4-methyl-benzenesulfonamide;
3-Chloro-N- [5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl] -4-methyl- benzenesulfonamide; N- [5-(4-Fluoro-2-methyl-phenyl)-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
N- [ 5- (2,4-Dichloro-phenyl) -pyridin-2-yl] -3-trifluoromethyl-benzenesulfonamide;
N- [5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
N- [ 5- (2-Chloro-phenyl) -pyridin-2-yl] -4-fluoro-benzenesulfonamide;
N-[5-(2-Chloro-phenyl)-6-methyl-pyridin-2-yl]-2,4-difluoro-benzenesulfonamide;
N- [5-(2,4-Dichloro-phenyl)-6-methyl-pyridin-2-yl] -2,4-difluoro- benzenesulfonamide;
2,4-Dichloro-N- [5-(2,4-dichloro-phenyl)-pyridin-2-yl] -6-methyl- benzenesulfonamide;
2,4-Dichloro-N-[5-(2-chloro-phenyl)-6-methyl-pyridin-2-yl] -benzenesulfonamide;
N-[5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide;
3-Chloro-N- [5-(4-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] - benzenesulfonamide;
N- [5-(4-Fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] -3-methyl- benzenesulfonamide;
N-[5-(5-Fluoro-2-methyl-phenyl)-pyridin-2-yl]-3-trifiuoromethyl- benzenesulfonamide;
N-[5-(5-Chloro-2-methyl-phenyl)-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide;
N- [5-(6-Chloro-2-fluoro-3-methyl-phenyl)-pyridin-2-yl] -4-fluoro- benzenesulfonamide;
3-Chloro-N- [5- (4-fiuoro-2-methyl-phenyl) -pyridin-2-yl] -benzenesulfonamide; 2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-6-methyl- benzenesulfonamide;
4-Fluoro-N- [5-(5-fluoro-2-methyl-phenyl)-6-methyl-pyridin-2-yl] - benzenesulfonamide;
N- [5-(2-Chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
2,4-Dichloro-N- [5-(2,3-dichloro-phenyl) -6-methyl-pyridin-2-yl] -6-methyl- benzenesulfonamide;
2,4-Dichloro-N-[5-(2-chloro-4-fluoro-phenyl)-6-methyl-pyridin-2-yl]-6-methyl- benzenesulfonamide;
N-[5-(2,4-Bis-trifluoromethyl-phenyl)-pyridin-2-yl]-3-chloro-benzenesulfonamide;
3-Chloro-N- [5- (2-chloro-phenyl) -4-methyl-pyridin-2-yl] -benzenesulfonamide;
N- [5-(2-Chloro-phenyl)-4-methyl-pyridin-2-yl] -3-trifluoromethyl- benzenesulfonamide;
3-Chloro-N- [5-(4-fluoro-2-methyl-phenyi)-4-methyi-pyridin-2-yl] - benzenesulfonamide;
N-[5-(4-Fluoro-2-methyl-phenyl)-4-methyl-pyridin-2-yl]-3-trifluoromethyl- benzenesulfonamide; and
2,4-Dichloro-N-[5-(4-fluoro-2-methyl-phenyl)-4-methyl-pyτidin-2-yl]-6-methyl- benzenesulfonamide.
20. A process for the preparation of a compound according to any one of claims 1 to 19 comprising the reaction of a compound according to formula
Figure imgf000097_0001
in the presence of a compound according to formula
Figure imgf000097_0002
wherein R to R7, A, E and G are defined as in claim 1.
21. Compounds according to any one of claims 1 to 19 for use as therapeutically active substance.
22. Compounds according to any one of claims 1 to 19 for the preparation of medicaments for the prophylaxis and therapy of illnesses which are caused by disorders associated with the enzyme llbeta-hydroxysteroid dehydrogenase 1.
23. A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 19 and a therapeutically inert carrier.
24. The use of a compound according to any one of claims 1 to 19 for the preparation of medicaments for the treatment and prophylaxis of diabetes, obesity, eating disorders, dyslipidemiae and hypertension.
25. The use of a compound according to any one of claims 1 to 19 for the preparation of medicaments for the treatment and prophylaxis of diabetes Type II.
26. A compound according to any one of claims 1 to 19, when manufactured according to a process of claim 20.
27. A method for the treatment and prophylaxis of diabetes, obesity, eating disorders, dyslipidemiae and hypertension, which method comprises administering an effective amount of a compound as defined in any one of claims 1 to 19.
28. A method for the treatment and prophylaxis of diabetes Type II, which method comprises administering an effective amount of a compound as defined in any one of claims 1 to 19.
29. The invention as hereinbefore described.
C ***
PCT/EP2005/007894 2004-07-28 2005-07-20 Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors WO2006010546A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
MX2007000789A MX2007000789A (en) 2004-07-28 2005-07-20 Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors.
AU2005266531A AU2005266531B2 (en) 2004-07-28 2005-07-20 Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
DK05776709T DK1789041T3 (en) 2004-07-28 2005-07-20 Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
NZ552398A NZ552398A (en) 2004-07-28 2005-07-20 Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors for treatment of diabetes
PL05776709T PL1789041T3 (en) 2004-07-28 2005-07-20 Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
DE602005008079T DE602005008079D1 (en) 2004-07-28 2005-07-20 ARYL PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS
EP05776709A EP1789041B1 (en) 2004-07-28 2005-07-20 Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
BRPI0513864-7A BRPI0513864A (en) 2004-07-28 2005-07-20 compounds, process for their manufacture, pharmaceutical compositions comprising them, their use and method for the treatment and / or prophylaxis of diseases
JP2007522984A JP4690402B2 (en) 2004-07-28 2005-07-20 Aryl-pyridine derivatives as 11-β-HSD1 inhibitors
CA2574875A CA2574875C (en) 2004-07-28 2005-07-20 Aryl-pyridine derivatives as 11-beta hsd1 inhibitors
IL180481A IL180481A (en) 2004-07-28 2007-01-01 Aryl-pyridine derivatives, processes for their preparation, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
NO20070458A NO20070458L (en) 2004-07-28 2007-01-24 Aryl-pyridine derivatives as 11-Beta-HSD1 inhibitors
HK07114003.9A HK1105592A1 (en) 2004-07-28 2007-12-20 Aryl-pyridine derivatives as 1-beta-hsd1 inhibitors
HR20080477T HRP20080477T3 (en) 2004-07-28 2008-09-26 Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04103639 2004-07-28
EP04103639.3 2004-07-28

Publications (2)

Publication Number Publication Date
WO2006010546A2 true WO2006010546A2 (en) 2006-02-02
WO2006010546A3 WO2006010546A3 (en) 2006-04-13

Family

ID=35427898

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007894 WO2006010546A2 (en) 2004-07-28 2005-07-20 Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors

Country Status (27)

Country Link
US (2) US7528159B2 (en)
EP (1) EP1789041B1 (en)
JP (1) JP4690402B2 (en)
KR (1) KR100926842B1 (en)
CN (1) CN100589803C (en)
AR (1) AR049739A1 (en)
AT (1) ATE400271T1 (en)
AU (1) AU2005266531B2 (en)
BR (1) BRPI0513864A (en)
CA (1) CA2574875C (en)
DE (1) DE602005008079D1 (en)
DK (1) DK1789041T3 (en)
ES (1) ES2309789T3 (en)
HK (1) HK1105592A1 (en)
HR (1) HRP20080477T3 (en)
IL (1) IL180481A (en)
MX (1) MX2007000789A (en)
MY (1) MY138941A (en)
NO (1) NO20070458L (en)
NZ (1) NZ552398A (en)
PL (1) PL1789041T3 (en)
PT (1) PT1789041E (en)
RU (1) RU2374239C2 (en)
SI (1) SI1789041T1 (en)
TW (1) TW200608972A (en)
WO (1) WO2006010546A2 (en)
ZA (1) ZA200700181B (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106423A2 (en) * 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010007794A1 (en) 2008-07-18 2010-01-21 興和株式会社 Novel spiro compound, and pharmaceutical preparation comprising the same
WO2010023931A1 (en) 2008-08-29 2010-03-04 興和株式会社 1-adamantylazetidin-2-one derivative and pharmaceutical preparation comprising same
WO2010050191A1 (en) 2008-10-29 2010-05-06 興和株式会社 1,2-diazetidin-3-one derivative and pharmaceutical agent comprising same
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8519142B2 (en) 2009-05-15 2013-08-27 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
WO2019149965A1 (en) * 2018-02-05 2019-08-08 Universite De Strasbourg Compounds and compositions for the treatment of pain
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US11926616B2 (en) 2018-03-08 2024-03-12 Incyte Corporation Aminopyrazine diol compounds as PI3K-γ inhibitors

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552398A (en) * 2004-07-28 2010-08-27 Hoffmann La Roche Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors for treatment of diabetes
PA8713501A1 (en) * 2006-02-07 2009-09-17 Wyeth Corp 11-BETA HYDROXIESTEROID DEHYDROGENASA INHIBITORS - 11ßHSD1
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
PT2686302T (en) * 2011-03-16 2016-11-02 Mitsubishi Tanabe Pharma Corp Sulfonamide compounds having trpm8 antagonistic activity
CA2865071C (en) 2012-02-22 2020-06-23 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors
RU2015124564A (en) * 2012-12-10 2017-01-12 Ф. Хоффманн-Ля Рош Аг DERIVATIVES OF BENZENESULPHONAMIDE AS RORc RECEPTOR MODULATORS
CN105175323B (en) * 2015-09-16 2017-12-22 浙江海翔药业股份有限公司 One kind prepares 2（4 acetamido benzenesulfonyls）The method of amido pyridine
KR102418518B1 (en) * 2020-08-05 2022-07-07 성균관대학교산학협력단 N-Heterocyclic selective alkylation method using sulfur ylides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0708098A1 (en) * 1994-10-07 1996-04-24 Sankyo Company Limited Oxime derivatives, their preparation and their therapeutic use
WO2003044009A1 (en) * 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003043999A1 (en) * 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2004011410A1 (en) * 2002-07-27 2004-02-05 Astrazeneca Ab Chemical compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552398A (en) * 2004-07-28 2010-08-27 Hoffmann La Roche Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors for treatment of diabetes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0708098A1 (en) * 1994-10-07 1996-04-24 Sankyo Company Limited Oxime derivatives, their preparation and their therapeutic use
WO2003044009A1 (en) * 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003043999A1 (en) * 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2004011410A1 (en) * 2002-07-27 2004-02-05 Astrazeneca Ab Chemical compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YAMANAKA, MOTOSUKE ET AL: "Imidazo[1,2-a]pyridines. II. Ozonolysis of imidazo[1,2-a]pyridines and synthesis of cardiotonic agents" XP002357771 retrieved from STN Database accession no. 1992:407853 & CHEMICAL & PHARMACEUTICAL BULLETIN , 40(3), 666-74 CODEN: CPBTAL; ISSN: 0009-2363, 1992, *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106423A3 (en) * 2005-04-07 2007-01-04 Pfizer Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
WO2006106423A2 (en) * 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
EP2351568A2 (en) 2006-05-04 2011-08-03 Boehringer Ingelheim International GmbH Uses of dpp-iv inhibitors
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010007794A1 (en) 2008-07-18 2010-01-21 興和株式会社 Novel spiro compound, and pharmaceutical preparation comprising the same
US8236789B2 (en) 2008-08-29 2012-08-07 Kowa Company, Ltd. 1-adamantyl azetidin-2-one derivatives and drugs containing same
WO2010023931A1 (en) 2008-08-29 2010-03-04 興和株式会社 1-adamantylazetidin-2-one derivative and pharmaceutical preparation comprising same
WO2010050191A1 (en) 2008-10-29 2010-05-06 興和株式会社 1,2-diazetidin-3-one derivative and pharmaceutical agent comprising same
US8252781B2 (en) 2008-10-29 2012-08-28 Kowa Company, Ltd. 1,2-diazetidin-3-one derivatives and drugs containing same
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8809545B2 (en) 2009-05-15 2014-08-19 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
US8519142B2 (en) 2009-05-15 2013-08-27 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2019149965A1 (en) * 2018-02-05 2019-08-08 Universite De Strasbourg Compounds and compositions for the treatment of pain
US11926616B2 (en) 2018-03-08 2024-03-12 Incyte Corporation Aminopyrazine diol compounds as PI3K-γ inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Also Published As

Publication number Publication date
DK1789041T3 (en) 2008-09-08
TW200608972A (en) 2006-03-16
JP2008508212A (en) 2008-03-21
PT1789041E (en) 2008-08-20
BRPI0513864A (en) 2008-05-20
US7528159B2 (en) 2009-05-05
US8211913B2 (en) 2012-07-03
PL1789041T3 (en) 2008-11-28
US20090149503A1 (en) 2009-06-11
DE602005008079D1 (en) 2008-08-21
KR20070026865A (en) 2007-03-08
IL180481A0 (en) 2007-06-03
CN100589803C (en) 2010-02-17
MX2007000789A (en) 2007-03-23
ES2309789T3 (en) 2008-12-16
AR049739A1 (en) 2006-08-30
RU2374239C2 (en) 2009-11-27
ZA200700181B (en) 2009-03-25
WO2006010546A3 (en) 2006-04-13
ATE400271T1 (en) 2008-07-15
NZ552398A (en) 2010-08-27
SI1789041T1 (en) 2008-10-31
HK1105592A1 (en) 2008-02-22
CA2574875C (en) 2010-09-28
JP4690402B2 (en) 2011-06-01
NO20070458L (en) 2007-01-24
RU2007107189A (en) 2008-09-10
US20060025455A1 (en) 2006-02-02
HRP20080477T3 (en) 2008-12-31
CA2574875A1 (en) 2006-02-02
AU2005266531B2 (en) 2008-11-20
IL180481A (en) 2011-05-31
EP1789041A2 (en) 2007-05-30
MY138941A (en) 2009-08-28
EP1789041B1 (en) 2008-07-09
KR100926842B1 (en) 2009-11-13
CN1988905A (en) 2007-06-27
AU2005266531A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
US7528159B2 (en) 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes
CA2571361C (en) Pyrimidine derivatives as 11beta-hsd1 inhibitors
US7482341B2 (en) Pyridines
AU2005289107B2 (en) Indozolone derivatives as 11b-HSD1 inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005776709

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 180481

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 552398

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200700181

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 07004263

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 12007500172

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/000789

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2574875

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200580025005.9

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1020077002036

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007522984

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005266531

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 778/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005266531

Country of ref document: AU

Date of ref document: 20050720

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005266531

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007107189

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020077002036

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005776709

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0513864

Country of ref document: BR

WWG Wipo information: grant in national office

Ref document number: 2005776709

Country of ref document: EP